Page last updated: 2024-12-05

enoxacin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Enoxacin is a synthetic fluoroquinolone antibacterial agent that is active against a broad spectrum of gram-positive and gram-negative bacteria. It is used to treat a variety of infections, including urinary tract infections, respiratory tract infections, and skin infections. Enoxacin is thought to work by inhibiting the activity of bacterial DNA gyrase, an enzyme that is essential for bacterial DNA replication. Enoxacin has been studied for its potential use in the treatment of a number of other conditions, including chronic prostatitis, gonorrhea, and tuberculosis. However, its use has been limited by the development of resistance in some bacteria.'
```

Enoxacin: A broad-spectrum 6-fluoronaphthyridinone antibacterial agent that is structurally related to NALIDIXIC ACID. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

enoxacin : A 1,8-naphthyridine derivative that is 1,4-dihydro-1,8-naphthyridine with an ethyl group at the 1 position, a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a piperazin-1-yl group at the 7 position. An antibacterial, it is used in the treatment of urinary-tract infections and gonorrhoea. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3229
CHEMBL ID826
CHEBI ID157175
SCHEMBL ID33963
MeSH IDM0023652

Synonyms (168)

Synonym
BIDD:GT0191
AB00052328-09
BRD-K78113049-001-05-5
AKOS015838626
nsc-629661
1, 6-fluoro-1,4-dihydro- 4-oxo-7-piperazinyl
MLS000069645
DIVK1C_000420
KBIO1_000420
NCI60_009618
almitil
enoxor
pd-107779
flumark
comprecin
penetrex
1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
enoxacinum [latin]
nsc 627409
1,8-naphthyridine-3-carboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-
ci 919
brn 3628995
enoxacine [french]
enoram
bactidan
nsc 629661
enoxacino [spanish]
ccris 5242
1,8-naphthyridine-3-carboxylic acid, 1,4-dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-
SPECTRUM_001539
OPREA1_147866
PRESTWICK3_000353
PRESTWICK_708
cas-74011-58-8
NCGC00016927-01
SPECTRUM5_001044
NCGC00178309-02
NCGC00178309-01
at 2266
pd107779
enoxin
PRESTWICK2_000353
IDI1_000420
BSPBIO_000445
SMP1_000113
BCBCMAP01_000009
pd 107779
1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,8-naphthyridine-3-carboxylic acid
at-2266
1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid
nsc629661
ci-919
74011-58-8
C06979
enoxacin
1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid
DB00467
enoxacin (usan/inn)
enx ,
penetrex (tn)
D00310
BSPBIO_003080
BPBIO1_000491
NCGC00023864-04
NCGC00023864-03
smr000058233
KBIO2_004587
KBIO2_007155
KBIO3_002580
KBIOGR_000651
KBIOSS_002019
KBIO2_002019
SPBIO_002366
SPECTRUM4_000166
NINDS_000420
SPECTRUM3_001570
SPBIO_001802
PRESTWICK0_000353
PRESTWICK1_000353
SPECTRUM2_001731
SPECTRUM1503215
NCGC00016927-02
HMS2092N20
HMS2090E10
e0762 ,
CHEMBL826 ,
nsc-758416
enoxacine
enoxacino
enoxacinum
1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
chebi:157175 ,
HMS501E22
enofloxacin
bdbm50296358
HMS1569G07
HMS1922I17
1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid
A837996
1-ethyl-6-fluoranyl-4-oxidanylidene-7-piperazin-1-yl-1,8-naphthyridine-3-carboxylic acid
1-ethyl-6-fluoro-4-oxo-7-piperazinylhydropyridino[2,3-b]pyridine-3-carboxylic acid
enoxacin [usan:inn:ban:jan]
unii-325ogw249p
325ogw249p ,
pharmakon1600-01503215
nsc758416
dtxcid002984
tox21_110688
dtxsid5022984 ,
enoxen
bactidron
enoksetin
HMS2233K20
CCG-39452
NCGC00016927-05
NCGC00016927-03
NCGC00016927-07
NCGC00016927-08
NCGC00016927-06
NCGC00016927-04
FT-0630825
NCGC00016927-10
EPITOPE ID:119069
S1756
BRD-K78113049-001-12-1
HMS3372A12
enoxacin [inn]
enoxacin [vandf]
1,8-naphthyridine-3-carboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)
enoxacin [mart.]
enoxacin [orange book]
enoxacin [who-dd]
enoxacin [usan]
enoxacin [mi]
gtpl8882
HY-B0268
SCHEMBL33963
tox21_110688_1
NCGC00016927-11
KS-5190
MLS006011976
1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydro[1,8]naphthyridine-3-carboxylic acid
enoxacin (penetrex)
enoxacin (hydrate)
AB00052328_10
AB00052328_11
mfcd00133308
SR-01000000202-2
sr-01000000202
enoxacin, analytical standard
HMS3655M08
SR-01000000202-3
SBI-0051788.P002
HMS3715H13
SW196857-3
BCP22623
Z1544404495
Q1639616
at 2266;ci 919
enoxacin sesquihydrate;at-2266 hydrate;ci-919 hydrate
BRD-K78113049-001-07-1
EN300-122627
abenox
j01ma04
enoxacin (mart.)
enoxacina
enoxacinum (latin)
1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-(1,8)naphthyridine-3-carboxylic acid

Research Excerpts

Overview

Enoxacin (EN) is a broad-spectrum antibiotic that has the ability of anti-osteoclastogenesis. It is structurally related to nalidixic acid used mainly in the treatment of urinary tract infections and gonorrhea.

ExcerptReferenceRelevance
"Enoxacin (EN) is a broad-spectrum antibiotic that has the ability of anti-osteoclastogenesis."( Immobilization of type I collagen/hyaluronic acid multilayer coating on enoxacin loaded titania nanotubes for improved osteogenesis and osseointegration in ovariectomized rats.
Li, H; Long, T; Nie, B; Yue, B; Zhang, S, 2019
)
1.47
"Enoxacin is a broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid used mainly in the treatment of urinary tract infections and gonorrhea. "( Evaluation of in vitro inhibitory effect of enoxacin on Babesia and Theileria parasites.
AbouLaila, M; Al-Aboody, MS; El-Sayed, SA; Elsify, A; Igarashi, I; Omar, MA; Rizk, MA; Salama, A, 2016
)
2.14
"Enoxacin is a small molecule that stimulates RNA interference (RNAi) and acts as a growth inhibitor selectively in cancer but not in untransformed cells. "( Click Quantitative Mass Spectrometry Identifies PIWIL3 as a Mechanistic Target of RNA Interference Activator Enoxacin in Cancer Cells.
Abell, NS; Cañeque, T; Mercado, M; Rodriguez, R; Xhemalce, B, 2017
)
2.11
"Enoxacin is a second-generation quinolone with increased antibacterial activity both in potency as well as in terms of broad spectrum against a wide range of clinically important pathogens over the first generation quinolones and produces its effect by inhibiting bacterial enzyme DNA gyrase. "( In vitro availability studies of enoxacin in presence of H2 receptor antagonists.
Arayne, MS; Hamza, E; Haroon, U; Sultana, N, 2007
)
2.06
"Enoxacin is a new quinolone carboxylic acid compound. "( In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim.
Chin, NX; Neu, HC, 1983
)
2.03
"Oral enoxacin appears to be a safe and effective method of treatment for anogenital infections caused by N. "( Comparison of enoxacin and ceftriaxone in the treatment of uncomplicated gonorrhea.
Benes, S; Covino, JM; Cummings, MC; Draft, K; McCormack, WM; Smith, BL,
)
1.01
"Enoxacin is a quinolone antibacterial agent currently being developed for oral and intravenous treatment of bacterial infections. "( Effects of oral cimetidine or ranitidine on the pharmacokinetics of intravenous enoxacin.
Eldon, MA; Misiak, PM; Sedman, AJ; Toothaker, RD, 1993
)
1.96
"Enoxacin is a 6-fluoronaphthyridinone antibacterial agent with good in vitro activity against Neisseria gonorrhoeae and most Gram-negative urinary tract pathogens. "( Enoxacin: a reappraisal of its clinical efficacy in the treatment of genitourinary tract infections.
Patel, SS; Spencer, CM, 1996
)
3.18
"Enoxacin is a second-generation quinolone derivative recently introduced in Spain. "( Enoxacin-induced photosensitivity: study of two cases.
Díaz-Pérez, JL; Gardeazabal, J; González, M; Izu, R; Landa, N; Ratón, JA, 1992
)
3.17
"Enoxacin is a new quinolone derivative that is well absorbed after oral administration and shows good efficacy against the pathogenic bacteria usually isolated in urinary infections. "( In vivo diffusion of enoxacin in healthy renal and adenomatous prostate tissue in man.
Charton, M; Timbal, Y, 1990
)
2.04
"Enoxacin is a fluorinated quinolone with potential clinical use in the treatment of serious infections. "( Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment.
Dudley, MN; George, B; Stolear, JC; Van der Auwera, P, 1990
)
2.05
"Enoxacin seems to be an excellent alternative treatment for this sexually transmitted disease."( Treatment of chancroid with enoxacin.
Mensing, H, 1985
)
1.28
"Oral enoxacin is a safe and efficacious alternative for the treatment of uncomplicated N."( Single dose enoxacin for the treatment of uncomplicated urogenital gonorrhea.
Albrecht, LM; Rybak, MJ; Schubiner, HH; Weiner, LM,
)
0.97
"Enoxacin appears to be a well tolerated, efficacious alternative to currently recommended therapy for patients with uncomplicated, anogenital gonorrhea including cases potentially caused by antibiotic resistant N."( Multicenter, comparative study of enoxacin and ceftriaxone for treatment of uncomplicated gonorrhea.
Black, JR; Handsfield, HH; Hook, EW; Pabst, KM; Siegel, NA; Smith, S,
)
1.13
"Enoxacin is a new fluoroquinolone compound structurally related to nalidixic acid."( Enoxacin: a new fluoroquinolone.
Bailey, EM; Jaber, LA; Rybak, MJ, 1989
)
2.44
"Enoxacin is a new fluoroquinolone that will be available as oral and intravenous preparations. "( Clinical overview of enoxacin.
Zinner, SH, 1989
)
2.04
"Enoxacin is a highly effective oral anti-infective agent with excellent bioavailability characteristics, a relatively slow rate of elimination and simple, well-defined requirements for dosage modification in patients with renal dysfunction."( Enoxacin absorption and elimination characteristics.
Toothaker, RD, 1989
)
2.44
"Enoxacin is a new addition to the class of 4-quinolone antibacterial drugs. "( Enoxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Henwood, JM; Monk, JP, 1988
)
3.16
"Enoxacin would seem to be a very effective drug in the treatment of uncomplicated urogenital gonorrhoea in female patients."( Treatment of uncomplicated urogenital gonorrhoea in women with a single dose of enoxacin.
Michel, MF; Stolz, E; Tegelberg-Stassen, MJ; van der Hoek, JC; van der Willigen, AH; van Joost, T; van Klingeren, B; van Vliet, HJ; Wagenvoort, JH, 1986
)
1.22
"Enoxacin is a new orally active, synthetic broad-spectrum antibacterial drug of the fluorinated quinolone class. "( The absorption and disposition of enoxacin in healthy subjects.
Bochner, F; Somogyi, AA, 1988
)
2
"Enoxacin is a safe and effective alternative to parenteral treatment of lower respiratory tract infections."( Enoxacin in the treatment of lower respiratory tract infections.
Arnaud, A; Frances, Y; Nourrit, J; Philip-Joet, F, 1988
)
2.44
"Enoxacin seems to be a good alternative to nalidixic acid for bacillary dysentery due to multiresistant shigella."( Treatment of bacillary dysentery: a comparison between enoxacin and nalidixic acid.
Butzler, JP; De Mol, P; Lagasse, R; Mets, T; Mutwewingabo, A; Vandepitte, J, 1987
)
1.24
"Enoxacin is a broad-spectrum quinolone-derivative antibiotic. "( Treatment of experimental Pseudomonas corneal ulcers with enoxacin, a quinolone antibiotic.
Bien, PA; Cohen, MA; Griffin, TJ; Heifetz, CL; Mehta, S; Sugar, A, 1986
)
1.96
"Enoxacin is a new quinolone-azaquinolone antibiotic that possesses in vitro activity against a broad spectrum of bacteria including Pseudomonas aeruginosa. "( Penetration of enoxacin into human bronchial mucosa.
Braude, PD; Marlin, GE; Somogyi, AA; Whelan, AJ, 1986
)
2.07
"Enoxacin (ENX) is a new derivative of pyridonecarboxylic acid and has a broad spectrum antibacterial activity. "( [Clinical experience of enoxacin in the treatment of nongonococcal urethritis].
Fujioka, H; Ichikawa, Y; Ishibashi, M; Matsuda, M; Matsui, T; Nakano, E; Okuyama, A; Sonoda, T; Takaha, M, 1987
)
2.02
"Enoxacin is a potent quinolone derivative with marked activity against gram-negative bacteria and staphylococci. "( Penetration of enoxacin into bronchial secretions.
Fong, IW; Simbul, M; Vandenbroucke, A, 1987
)
2.07

Effects

Enoxacin has been identified as a small molecule inhibitor of binding between the B2-subunit of vacuolar H+-ATPase and microfilaments. It has been shown to be an effective agent for the treatment of urinary-tract, genital-traction, and skin and soft-tissue infections.

ExcerptReferenceRelevance
"Bis-enoxacin, which has both antiresorptive and antibiotic activities, was more effective than alendronate, which acts only as an antiresorptive."( Periodontitis in rats induces systemic oxidative stress that is controlled by bone-targeted antiresorptives.
Chukkapalli, SS; Holliday, LS; Kesavalu, L; Oktay, S; Rivera-Kweh, MF; Velsko, IM, 2015
)
0.9
"Enoxacin has desirable efficacy and few adverse effects on type III A prostatitis."( [Enoxacin for type III A prostatitis: a clinical observation].
Chen, Z; Chen, ZQ; Deng, RJ; Ye, ZQ; Zhou, XC, 2010
)
2.71
"Enoxacin has been identified as a small molecule inhibitor of binding between the B2-subunit of vacuolar H+-ATPase (V-ATPase) and microfilaments. "( Enoxacin directly inhibits osteoclastogenesis without inducing apoptosis.
Arana-Chavez, V; Bradaschia-Correa, V; Caridad, AR; Catalfamo, D; Holliday, LS; Neubert, JK; Ostrov, DA; Toro, EJ; Wallet, SM; Wronski, TJ; Zuo, J, 2012
)
3.26
"Enoxacin has been shown to be an effective agent for the treatment of urinary-tract, genital-tract, and skin and soft-tissue infections, including those that currently require injectable antimicrobial agents or that are resistant to conventional therapy."( Enoxacin: a new fluoroquinolone.
Bailey, EM; Jaber, LA; Rybak, MJ, 1989
)
2.44
"Enoxacin (ENX) has been reported to raise significantly plasma levels of theophylline (TP) in humans. "( Interaction of enoxacin with theophylline in rats.
Hashimoto, M; Kamaura, M; Mizuki, Y; Sekine, Y; Yamaguchi, T, 1989
)
2.07
"Enoxacin has excellent in vitro activity against H ducreyi, and a randomised clinical trial of three doses of enoxacin 400 mg at intervals of 12 hours compared with a single dose of trimethoprim/sulphametrole (TMP/SMT) 640/3200 mg was therefore conducted."( Treating chancroid with enoxacin.
D'Costa, LJ; Kunimoto, DY; Naamara, W; Ndinya-Achola, JO; Nsanze, H; Plummer, FA; Ronald, AR, 1988
)
1.3
"Enoxacin has been shown to be an effective well tolerated and convenient treatment for gonorrhoea."( Enoxacin in the treatment of sexually transmitted diseases.
Bohbot, JM; Catalan, F; Siboulet, A, 1988
)
2.44
"Enoxacin has shown a broad spectrum of action and antibacterial activity in general higher that than of three currently available antibiotics."( In vitro antibacterial activity of enoxacin, a new pyridonecarboxylic acid.
Bondi, M; Casolari, C; Fabio, U; Galletti, F; Manicardi, G; Messi, P; Neglia, R, 1987
)
1.27

Treatment

Enoxacin treatment significantly up-regulated miRNAs in dnTGFβRII CD8 T cells and effectively treated autoimmune cholangitis in mice. Treatment was efficacious in 89.2% of cases, in presence of either Gram positive or Gram negative bacteria.

ExcerptReferenceRelevance
"Enoxacin treatment significantly up-regulated miRNAs in dnTGFβRII CD8 T cells and effectively treated autoimmune cholangitis in dnTGFβRII mice."( Enoxacin Up-Regulates MicroRNA Biogenesis and Down-Regulates Cytotoxic CD8 T-Cell Function in Autoimmune Cholangitis.
Adams, D; Bednar, KJ; Flavell, RA; Gershwin, ME; Huang, W; Itoh, A; Kachapati, K; Leung, PSC; Ridgway, WM; Wu, Y; Zhang, W, 2021
)
2.79
"Enoxacin treatment down-regulated miR-34-5p and did not further extend lifespan of long-lived mir-34 mutants."( Enoxacin extends lifespan of C. elegans by inhibiting miR-34-5p and promoting mitohormesis.
Camara, H; De-Souza, EA; Ferraz, RC; Lopes-Ramos, CM; Lovci, MT; Massirer, KB; Mazzotti, DR; Mori, MA; Parmigiani, RB; Pinca, APF; Pinto, S; Sato, VN; Tonon, G; Wurtele, M, 2018
)
2.64
"Enoxacin treatment was efficacious in 89.2% of cases, in presence of either Gram positive or Gram negative bacteria.(ABSTRACT TRUNCATED AT 250 WORDS)"( [Treatment of male genital infections with enoxacin].
Andreini, F; Bartelloni, M; Campa, M; Canale, D; Di Coscio, M; Giorgi, P; Giorgi, PM; Meschini, P; Poggi, MS; Turchi, P, 1989
)
1.26
"Enoxacin treatment for 3 or 5 days and vancomycin treatment for 5 days significantly reduced bacterial counts of vegetations compared with those in untreated control rabbits after 1 day of infection."( Enoxacin compared with vancomycin for the treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis.
Boscia, JA; Gilbert, M; Kaye, D; Kobasa, WD, 1986
)
2.44
"Treatment with enoxacin reduced the association of V-ATPase subunits with the detergent-insoluble cytoskeleton."( Enoxacin directly inhibits osteoclastogenesis without inducing apoptosis.
Arana-Chavez, V; Bradaschia-Correa, V; Caridad, AR; Catalfamo, D; Holliday, LS; Neubert, JK; Ostrov, DA; Toro, EJ; Wallet, SM; Wronski, TJ; Zuo, J, 2012
)
2.16
"Pretreatment with enoxacin decreased the total clearance (CLT) and elimination rate constant (Kel) of theophylline by 50% and 46%, respectively, without changing the volume of distribution (Vd), but there were no significant change in any pharmacokinetic parameter when fluconazole was administered."( Effect of fluconazole on theophylline disposition in humans.
Konishi, H; Morita, K; Yamaji, A, 1994
)
0.61
"Pretreatment with enoxacin significantly delayed the elimination of MPX from plasma."( The possible mechanism of interaction between xanthines and quinolone.
Apichartpichean, R; Hasegawa, T; Kuzuya, T; Miyamoto, K; Muraoka, I; Nadai, M; Takagi, K, 1990
)
0.6
"Treatment with enoxacin resulted in 97.5% (second day), respectively 92.5% (seventh day) bacteriologically sterile urine cultures, whereas the rate of sterile urines following amoxicillin reached only 72.5% (second day), and 65% (seventh day), respectively."( [Comparative studies of enoxacin and amoxicillin for acute uncomplicated cystitis in women].
Bischoff, W, 1986
)
0.92
"Treatment with enoxacin or ofloxacin produced intrapulmonary killing of H."( Comparative evaluation of enoxacin, ofloxacin, ampicillin, and chloramphenicol for treatment of experimental Haemophilus influenzae pneumonia.
Borner, K; Kemmerich, B; Pennington, JE, 1987
)
0.91

Toxicity

Enoxacin appears a very effective and safe drug in the treatment of the infections of the lower respiratory tract. The bronchodilator theophylline has been associated with significant neurologic and other adverse effects.

ExcerptReferenceRelevance
" Enoxacin appears a very effective and safe drug in the treatment of the infections of the lower respiratory tract."( Efficacy and safety of enoxacin in the treatment of respiratory infections.
Della Torre, F; Fraschini, F; Scaglione, F; Scarpazza, G, 1989
)
1.5
"Concomitant use of the bronchodilator theophylline and the antibacterial agent enoxacin has been associated with significant neurologic and other adverse effects."( Effect of enoxacin on theophylline neurotoxicity.
Hoffman, A; Levy, G, 1989
)
0.91
" In addition, the microbiological effectiveness and the occurrence of adverse effects on spermatogenesis were evaluated in the patient group."( [Efficacy of enoxacin in the treatment of prostatitis-vesiculitis: its absence of toxicity on spermatogenesis].
Barletta, D; Bellitti, P; Bonadio, M; Caraccio, N; Gasperi, M; Maccanti, O; Monzani, F; Pucci, E, 1995
)
0.66
"The absence of adverse effects, both general and specifically on spermatogenesis, may be related to the restriction of indications and the brevity of the therapeutic cycles."( [Efficacy of enoxacin in the treatment of prostatitis-vesiculitis: its absence of toxicity on spermatogenesis].
Barletta, D; Bellitti, P; Bonadio, M; Caraccio, N; Gasperi, M; Maccanti, O; Monzani, F; Pucci, E, 1995
)
0.66
"To elucidate the mechanism of phototoxicity induced as a side effect by some of the new quinolone antibiotics, we studied sparfloxacin (SPFX), lomefloxacin, enoxacin, ofloxacin, and ciprofloxacin."( Participation of reactive oxygen species in phototoxicity induced by quinolone antibacterial agents.
Arakane, K; Hirobe, M; Mashiko, S; Nagano, T; Ryu, A; Umezawa, N, 1997
)
0.49
" From these results, it is concluded that a 2-week treatment is sufficient to detect toxic effects of ENX on reproductive organs in male rats, and that testicular toxicity induced by ENX is associated with germ cell apoptosis."( Collaborative work to evaluate toxicity on male reproductive organs by repeated dose studies in rats 19). Effects of two-week repeated dosing of enoxacin on the male reproductive organs.
Furubo, S; Kawamura, Y; Kizawa, K; Sanzen, T, 2000
)
0.51
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32

Pharmacokinetics

Enoxacin (250 mg/l) demonstrated the highest peak concentration (median) in the urine (0-6 h) The pharmacokinetics of enoxacins in sputum were similar to those in plasma, the only significant difference being between the mean times to reach peak concentration.

ExcerptReferenceRelevance
" The pharmacokinetic parameters of the two drugs were estimated by model-independent methods."( Pharmacokinetic characteristics of N7-substituted theophylline derivatives and their interaction with quinolone in rats.
Apichartpichean, R; Hasegawa, T; Muraoka, I; Nabeshima, T; Nadai, M; Takagi, K, 1991
)
0.28
"The pharmacokinetic properties of the new fluoroquinolones are characterized by a high volume of distribution, long biological half-life, low serum protein binding, elimination by renal and extrarenal mechanisms with high total and renal clearances, limited biotransformation and moderate to excellent bioavailability after oral administration."( Quinolone pharmacokinetics and metabolism.
Boeckk, M; Borner, K; Deppermann, N; Höffken, G; Koeppe, P; Lode, H, 1990
)
0.28
" For the other new quinolones, a decrease in glomerular filtration rate below 20-30 ml/min induces an increase in terminal half-life and a decrease in plasma and renal clearance, related to the degree of renal impairment."( Pharmacokinetics of quinolones in renal insufficiency.
Borsa-Lebas, F; Dhib, M; Fillastre, JP; Humbert, G; Leroy, A; Moulin, B, 1990
)
0.28
"Quinolone is reported to interact with caffeine, often resulting in an increase both in the plasma half-life and AUC, a decrease in total plasma clearance, and little change in the absorption rate constant and maximum plasma level."( Pharmacokinetic determination of relative potency of quinolone inhibition of caffeine disposition.
Barnett, G; Carbó, M; de la Torre, R; Segura, J, 1990
)
0.28
" Pharmacokinetic parameters (mean +/- standard deviation) were calculated by using a noncompartmental PK model according to creatinine clearances (in milliliters per minute)."( Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment.
Dudley, MN; George, B; Stolear, JC; Van der Auwera, P, 1990
)
0.6
"In order to clarify the possibility of pharmacokinetic interaction between quinolone and fenbufen, the plasma concentration-time profiles and serum protein binding of enoxacin, fenbufen and its active metabolite, felbinac, were investigated in rats."( A minor possibility of pharmacokinetic interaction between enoxacin and fenbufen in rats.
Hayashibara, M; Ichikawa, N; Iwamoto, K; Katagiri, Y; Naora, K, 1990
)
0.72
" In this review we compare key pharmacokinetic parameters of the most important 4-quinolones."( [Enoxacin--comparative pharmacokinetics and tissue penetration].
Metz, R; Morgenroth, A; Naber, KG; Sörgel, F, 1989
)
1.19
" The pharmacokinetic profile of enoxacin is similar to that of ofloxacin, achieving higher plasma and tissue concentrations and possessing a longer half-life than norfloxacin or ciprofloxacin."( Enoxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Henwood, JM; Monk, JP, 1988
)
2
"An in vitro pharmacokinetic model was used to study the comparative antibacterial activities of multiple-dose regimens of enoxacin and netilmicin."( Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance.
Blaser, J; Groner, MC; Stone, BB; Zinner, SH, 1987
)
0.79
" A dosing schedule for the quinolones was proposed on the basis of pharmacokinetic parameters and microbiologic activity."( Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule.
Andrews, JM; Griggs, D; Wise, R,
)
0.13
" Total body clearance decreased and elimination half-life increased with increasing dose."( Pharmacokinetics of intravenous and oral enoxacin in healthy volunteers.
Black, A; Chang, T; Dunky, A; Latts, J; Sedman, A; Welling, PG; Wolf, R, 1988
)
0.54
" In addition, pharmacokinetic parameters of enoxacin and its 4-oxo metabolite were determined for plasma and sputum from 19 patients treated with enoxacin, 400 or 600 mg bd, for a respiratory tract infection."( Pharmacokinetics of enoxacin and its penetration into bronchial secretions and lung tissue.
Baars, AM; van Herwaarden, CL; Vree, TB; Wijnands, WJ, 1988
)
0.86
" Plasma half-life (10."( The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin.
Frost, RW; Kinkel, AW; Nix, DE; Schentag, JJ; Schultz, RW; Sedman, AJ; Thomas, DJ, 1988
)
0.5
" The pharmacokinetic studies showed high enoxacin concentrations in the secretions, pus, and tissues studied, especially in those of the middle ear and the sinuses."( Clinical and pharmacokinetic studies on enoxacin in ear, nose and throat infections.
Federspil, PJ; Lind, A; Schmidt, B; Tiesler, E, 1986
)
0.8
" single) and showed no significant effect on total body clearance, serum half-life (T1/2) and AUC of theophylline, while enoxacin by the same pretreatment increased significantly serum theophylline concentrations and resulted in significant effect on all the pharmacokinetic parameters."( Lack of effect of ofloxacin on theophylline pharmacokinetics in rats.
Miyazaki, K; Okazaki, O; Tachizawa, H, 1987
)
0.48
"The pharmacokinetic properties of the new quinolones are characterised by a high volume of distribution, long biological half-life, low serum protein binding, elimination mainly by the kidneys, high total and renal clearances, limited biotransformation and a moderate to excellent bioavailability after oral administration."( Comparative pharmacokinetics of new quinolones.
Borner, K; Glatzel, P; Höffken, G; Koeppe, P; Lode, H; Olschewski, P; Prinzing, C; Reimnitz, D; Sievers, B; Wiley, R, 1987
)
0.27
" Enoxacin (250 mg/l) demonstrated the highest peak concentration (median) in the urine (0-6 h), followed by ciprofloxacin (237 mg/l) and norfloxacin (157 mg/l) as determined by the HPLC assay."( Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose.
Kinzig-Schippers, M; Naber, KG; Sörgel, F; Well, M, 1998
)
1.46
"In order to obtain an experimental evidence for Enoxacin(ENX) to be correctly used in clinical treatment, we studied the effect of ENX on the pharmacokinetic parameters of theophylline(TP)."( [Effect of enoxacin on pharmacokinetics of theophylline in rats].
Bao, D; Kuang, X; Liu, D, 1999
)
0.95
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" Pharmacokinetic profiles were obtained for days 1 to 6 and 12 to 19."( Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide.
Elmlinger, M; Herzog, R; Hinder, M; Huennemeyer, A; Lahu, G; Nassr, N; Ruth, P, 2011
)
0.68
" This method can be applied to the pharmacokinetic study of norfloxacin and enoxacin after repeated administration to assess changes in CYP1A2 activity in healthy subjects."( A simple chromatographic method for determining norfloxacin and enoxacin in pharmacokinetic study assessing CYP1A2 inhibition.
Homma, M; Kobayashi, D; Kobayashi, T; Kohda, Y; Momo, K, 2011
)
0.84

Compound-Compound Interactions

ExcerptReferenceRelevance
"The effects of enoxacin, a new quinolone antibacterial agent, and its combination with 4-biphenylacetate (BPA), an active metabolite of the non-steroidal antiinflammatory agent fenbufen, were examined on population spikes induced by electrical stimulation of the stratum radiatum in the CA1 pyramidal cell layer in rat hippocampal slices."( Effects of enoxacin and its combination with 4-biphenylacetate, an active metabolite of fenbufen, on population spikes in rat hippocampal slices.
Hori, S; Ito, T; Kadokawa, T; Miura, Y; Miyahara, T; Shimada, J, 1991
)
1.02
"The antifungal activity of amphotericin B (AMB), mepartricin (MEPA), 5-fluorocytosine (5FC) and three imidazoles was tested in combination with each of four quinolones against 60 clinical yeast isolates."( In-vitro activity of antifungal agents in combination with four quinolones.
Petrou, MA; Rogers, TR, 1988
)
0.27
"Convulsant activity of pazufloxacin mesilate (PZFX mesilate), a new quinolone antibacterial agent for intravenous use, in combination with nonsteroidal anti-inflammatory drug (NSAID) was investigated in mice after intravenous or intracerebroventricular administration."( [Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate, a new quinolone antibacterial agent for intravenous use: convulsions in mice after intravenous or intracerebroventricular administration].
Fukuda, H; Kawamura, Y, 2002
)
0.31

Bioavailability

Enoxacin is a new quinolone derivative that is well absorbed after oral administration and shows good efficacy against the pathogenic bacteria usually isolated in urinary infections. Ranitidine pretreatment reduced enoxacins oral bioavailability by an average of 26%.

ExcerptReferenceRelevance
" Ranitidine pretreatment reduced enoxacin oral bioavailability by an average of 26%."( Effect of gastric acidity on enoxacin absorption.
Lebsack, ME; Nix, D; Norman, AM; Ryerson, B; Schentag, JJ; Sedman, AJ; Toothaker, RD; Welage, L, 1992
)
0.86
"Enoxacin is a new quinolone derivative that is well absorbed after oral administration and shows good efficacy against the pathogenic bacteria usually isolated in urinary infections."( In vivo diffusion of enoxacin in healthy renal and adenomatous prostate tissue in man.
Charton, M; Timbal, Y, 1990
)
2.04
"The pharmacokinetic properties of the new fluoroquinolones are characterized by a high volume of distribution, long biological half-life, low serum protein binding, elimination by renal and extrarenal mechanisms with high total and renal clearances, limited biotransformation and moderate to excellent bioavailability after oral administration."( Quinolone pharmacokinetics and metabolism.
Boeckk, M; Borner, K; Deppermann, N; Höffken, G; Koeppe, P; Lode, H, 1990
)
0.28
"Quinolone is reported to interact with caffeine, often resulting in an increase both in the plasma half-life and AUC, a decrease in total plasma clearance, and little change in the absorption rate constant and maximum plasma level."( Pharmacokinetic determination of relative potency of quinolone inhibition of caffeine disposition.
Barnett, G; Carbó, M; de la Torre, R; Segura, J, 1990
)
0.28
" Enoxacin steady-state pharmacokinetics and bioavailability were determined following repeated 400-mg intravenous (i."( Pharmacokinetics and bioavailability of intravenous-to-oral enoxacin in elderly patients with complicated urinary tract infections.
Dudley, MN; Marchbanks, CR; Mayer, KH; Mikolich, DJ; Zinner, SH, 1990
)
1.43
"Enoxacin, a new fluoroquinolone antibiotic, is rapidly and extensively absorbed after oral administration and has a bioavailability independent of dose and only slightly delayed by concurrent food."( Enoxacin absorption and elimination characteristics.
Toothaker, RD, 1989
)
3.16
" Absolute oral bioavailability averaged 89%, and was independent of the dose administered."( Pharmacokinetics of intravenous and oral enoxacin in healthy volunteers.
Black, A; Chang, T; Dunky, A; Latts, J; Sedman, A; Welling, PG; Wolf, R, 1988
)
0.54
" They are well absorbed after oral administration, and some achieve serum and tissue levels well exceeding the minimal inhibitory concentrations for susceptible bacteria."( Symposium on antimicrobial agents. The quinolones.
Walker, RC; Wright, AJ, 1987
)
0.27
"The pharmacokinetic properties of the new quinolones are characterised by a high volume of distribution, long biological half-life, low serum protein binding, elimination mainly by the kidneys, high total and renal clearances, limited biotransformation and a moderate to excellent bioavailability after oral administration."( Comparative pharmacokinetics of new quinolones.
Borner, K; Glatzel, P; Höffken, G; Koeppe, P; Lode, H; Olschewski, P; Prinzing, C; Reimnitz, D; Sievers, B; Wiley, R, 1987
)
0.27
" These results strongly suggest that adsorption of quinolones by aluminum hydroxide reprecipitated in the small intestine would play an important role in the reduced bioavailability of quinolones after coadministration with aluminum-containing antacids."( Mechanistic study of inhibition of levofloxacin absorption by aluminum hydroxide.
Aoki, H; Fujisawa, C; Hakusui, H; Kurata, T; Ohshima, Y; Okazaki, O; Tanaka, M, 1993
)
0.29
" Enoxacin is rapidly absorbed, with a high oral bioavailability (87 to 91%)."( Enoxacin: a reappraisal of its clinical efficacy in the treatment of genitourinary tract infections.
Patel, SS; Spencer, CM, 1996
)
2.65
" Recently a new method has been proposed to determine absolute bioavailability in the absence of intravenous dose."( Prediction of absolute bioavailability for drugs using oral and renal clearance following a single oral dose: a critical view.
Mahmood, I, 1997
)
0.3
"The poor bioavailability and therapeutic response exhibited by conventional ophthalmic solutions due to rapid precorneal elimination of the drug may be overcome by the use of a gel system."( Preparation and evaluation of sustained ophthalmic gel of enoxacin.
Li, J; Liu, Z; Nie, S; Pan, W; Yang, X; Zhang, L, 2005
)
0.57
" These "in combo" PAMPA data were used to predict the human absolute bioavailability of the ampholytes."( The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
Avdeef, A; Sun, N; Tam, KY; Tsinman, O, 2010
)
0.36
" Pharmacokinetic parameters such as oral clearance, oral volume of distribution of the central compartment, time to reach maximum plasma concentration, absorption rate constant, and half-life in humans were predicted from animals using allometric scaling."( Prediction of Plasma Concentration-time Profiles of Drugs in Humans from Animals Following Oral Administration: An Allometric Approach.
Mahmood, I, 2016
)
0.43
" Compound 12g with MIC values of 5 μg/ml as a representative may possess better oral bioavailability and indicated high permeability by the parallel artificial membrane permeation assay of the blood-brain barrier (PAMPA-BBB)."( Discovery of novel anti-tuberculosis agents with pyrrolo[1,2-a]quinoxaline-based scaffold.
An, Q; Deng, Y; Liu, P; Luo, Y; Sang, Z; Tang, Y; Wang, T; Yang, T; Yang, Y; Zhang, T, 2018
)
0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Study was done to determine the concomitant serum and bronchial concentrations of oral enoxacin after dosing with 600 mg, single dose; 400 mg,single dose; and 400 mg every 12 h, four doses. Plasma enoxAcin concentrations may be slightly higher in elderly subjects, but this change does not necessitate dosage adjustment in older patients.

ExcerptRelevanceReference
" In conclusion, enoxacin showed a good antibacterial activity, but it could be necessary to lower daily dosage and to extend the treating period to prevent side effects."( [The effectiveness of enoxacin for the treatment of complicated urinary tract infection].
Germinario, C; Quarto, M; Schena, FP; Viggiani, N,
)
0.79
" The careful monitoring of serum theophylline level and modification of theophylline dosage in patients receiving enoxacin and theophylline were recommended."( [Effect of enoxacin on theophylline pharmacokinetics].
Liu, YN, 1992
)
0.88
" The trough SBAs of the 4 fluoroquinolones suggest that the time interval of administration of CPLX and OFLX should be more than 8 hours, but increase of the dosage or shortening of the time interval between the administrations is recommended for ENX and NFLX."( Comparison of serum bactericidal activity of 4 fluoroquinolones in healthy volunteers.
Liu, YN; Sun, XD; Wang, R; Zhao, HZ, 1992
)
0.28
" We studied the diffusion of enoxacin in healthy renal tissue (13 patients) and adenomatous prostate tissue (16 patients) in surgical patients dosed with enoxacin preoperatively."( In vivo diffusion of enoxacin in healthy renal and adenomatous prostate tissue in man.
Charton, M; Timbal, Y, 1990
)
0.89
" Enoxacin was administered at the daily dosage of 300 mg every 12 hours for 10 days."( [Enoxacin in the treatment of asymptomatic bacteriuria in patients with prostatic adenoma].
Beghelli, R; Cortecchia, W; D'Amato, G; Dal Pra, ML; Emili, E; Frigola, M; Lo Cigno, M; Soli, M, 1991
)
2.1
" The dose-response relationships showed that the effect of enoxacin was 100 times potentiated in the presence of BPA (10(-5) M)."( Effects of enoxacin and its combination with 4-biphenylacetate, an active metabolite of fenbufen, on population spikes in rat hippocampal slices.
Hori, S; Ito, T; Kadokawa, T; Miura, Y; Miyahara, T; Shimada, J, 1991
)
0.91
" Dosage adjustments are required, particularly in severe renal failure and for the drugs almost exclusively excreted, in unchanged form, via the renal route."( Pharmacokinetics of quinolones in renal insufficiency.
Borsa-Lebas, F; Dhib, M; Fillastre, JP; Humbert, G; Leroy, A; Moulin, B, 1990
)
0.28
") and oral dosing by using compartmental and noncompartmental methods in 10 elderly (mean age, 73."( Pharmacokinetics and bioavailability of intravenous-to-oral enoxacin in elderly patients with complicated urinary tract infections.
Dudley, MN; Marchbanks, CR; Mayer, KH; Mikolich, DJ; Zinner, SH, 1990
)
0.52
" Enoxacin was administered at the daily dosage of 400 mg every 12 hours for 10 days starting from the enrollment."( [Enoxacin in the treatment of bacterial prostato-cystitis].
Austoni, E; Dal Prà, ML; Mandressi, A; Mantovani, F; Mascheroni, E; Montanari, E; Pisani, E, 1989
)
2.1
" Dosage of each quinolone was 200 mg twice daily for four days, starting three days prior to the theophylline infusion."( Drug-drug interactions affecting fluoroquinolones.
Guelen, PJ; Janssen, TJ; Vree, TB; Wijnands, GJ, 1989
)
0.28
" Hence when these 2 agents are given concurrently, careful monitoring of theophylline concentrations and/or dosage adjustments are recommended."( Tissue penetration and clinical efficacy of enoxacin in respiratory tract infections.
Wood, MJ, 1989
)
0.54
" Plasma enoxacin concentrations may be slightly higher in elderly subjects, but this change does not necessitate dosage adjustment in older patients with adequate renal function."( Enoxacin absorption and elimination characteristics.
Toothaker, RD, 1989
)
2.15
" Concomitant dosing of ENX with TP significantly elongated plasma elimination half-life of TP, which led to a marked increase in the maximum plasma TP level after repeated administrations of both drugs."( Interaction of enoxacin with theophylline in rats.
Hashimoto, M; Kamaura, M; Mizuki, Y; Sekine, Y; Yamaguchi, T, 1989
)
0.63
" The addition of enoxacin (400 mg, twice daily) to a theophylline dosing regimen (150 mg, twice daily) resulted in an immediate fall in plasma theophylline metabolite concentrations."( The theophylline-enoxacin interaction: II. Changes in the disposition of theophylline and its metabolites during intermittent administration of enoxacin.
Koup, JR; Rogge, MC; Sedman, AJ; Solomon, WR; Wagner, JG; Welling, PG, 1989
)
0.96
" An increase in theophylline concentration occurred in 15 of 16 patients receiving simultaneous administration of theophylline, without clinical evidence of toxicity when theophylline dosage was reduced and enoxacin continued."( Enoxacin in acute exacerbations of chronic bronchitis: a comparison with amoxycillin.
Blogie, M; Carpiaux, JP; Glupczynski, Y; Prigogine, T; Schmerber, JS; Yourassowsky, E, 1988
)
1.9
" A dosing schedule for the quinolones was proposed on the basis of pharmacokinetic parameters and microbiologic activity."( Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule.
Andrews, JM; Griggs, D; Wise, R,
)
0.13
"The ability of enoxacin to penetrate into sputum and its distribution and elimination characteristics after dosing to steady state were determined in six subjects with permanent tracheostomies."( Pharmacokinetics and sputum penetration of enoxacin after twice daily oral dosing for seven days.
Dobbs, BR; Edwards, IR; Gazeley, LR; Stewart, IA, 1988
)
0.89
" Further studies were needed to determine the relationship between the side effects induced by enoxacin and the theophylline dosage or its plasma concentration since side effects were experienced in all the subjects concomitantly administered enoxacin."( Interaction between theophylline and enoxacin.
Hasegawa, T; Satake, T; Suzuki, R; Takagi, K; Watanabe, T; Yamaki, K, 1988
)
0.77
" The patients were divided into 5 groups according with the timing of sampling: 1, 3, 6, 12 hours after dosing at day 3 (group I, II, III, IV), 3 hours after dosing at day 1, 2 and 3 (group V)."( [Diffusion, in the bronchial mucus, of enoxacin administered by oral route in man].
Benard, Y; Malbruny, B; Morel, C; Vergnaud, M, 1987
)
0.54
" The minimal erythema dose of UVA light was reduced by a mean of 45% in three of the twenty patients receiving the 800 mg daily dosage of enoxacin."( Efficacy of enoxacin in the treatment of bacterial infections of the skin with regards to photosensitization.
Petri, H; Tronnier, H, 1986
)
0.85
" AT-2266 was administered at a daily dosage of 600 mg in one dose to 14 patients, 2 doses to 10 patients and 3 doses to 98 patients."( [Epidemiologic and therapeutic studies on gonorrheal infections--use of AT-2266--Sapporo Clinical Research Group for STD].
Gohro, T; Henmi, I; Inoke, T; Kato, S; Kumamoto, Y; Saka, T; Sakai, S; Tabata, S; Tamate, H; Tanda, H, 1986
)
0.27
"AT-2266 tablets were administered orally in a daily dosage of 600 mg for 7 consecutive days as treatment of non-gonorrheal urethritis in 106 cases."( [Therapeutic studies on male non-gonorrheal urethritis--use of AT-2266--Sapporo Clinical Research Group for STD].
Gohro, T; Henmi, I; Inoke, T; Kato, S; Kumamoto, Y; Saka, T; Sakai, S; Tabata, S; Tamate, H; Tanda, H, 1986
)
0.27
" AT-2266 was administered in a daily dosage of 600 mg (in 3 divided doses) for 14 days."( [Therapeutic studies on chronic prostatitis--use of AT-2266--Sapporo Clinical Research Group for STD].
Gohro, T; Henmi, I; Inoke, T; Kato, S; Kumamoto, Y; Saka, T; Sakai, S; Tabata, S; Tamate, H; Tanda, H, 1986
)
0.27
" No alteration in enoxacin dosing in the elderly compared with that in younger patients is suggested."( The pharmacokinetics of enoxacin in elderly patients.
Baker, SL; Griggs, D; Misra, M; Wise, R, 1987
)
0.91
" A study was done to determine the concomitant serum and bronchial concentrations of oral enoxacin after dosing with 600 mg, single dose; 400 mg, single dose; and 400 mg every 12 h, four doses."( Penetration of enoxacin into bronchial secretions.
Fong, IW; Simbul, M; Vandenbroucke, A, 1987
)
0.85
", twice daily for 11 days in a sustained release dosage form."( Enoxacin--a potent inhibitor of theophylline metabolism.
Beckmann, J; Elsässer, W; Gundert-Remy, U; Hertrampf, R, 1987
)
1.72
"We reviewed, the structure, pharmacokinetic properties, mode of actions, antibacterial spectrum, therapeutic dosage and side effects of fluoroquinolones in this article."( [Fluoroquinolones].
Akalin, E; Baykal, M, 1987
)
0.27
" It is difficult to generalize their clinical usefulness, since these agents exhibit different pharmacokinetic profiles, antimicrobial activity (with varied minimum inhibitory concentrations among similar organisms), and dosage regimens."( Review of the 4-quinolones.
Eggleston, M; Park, SY, 1987
)
0.27
" In dogs with meningitis, a dosage of 12."( Diffusion of enoxacin into the cerebrospinal fluid in dogs with healthy meninges and with experimental meningitis.
Armengaud, A; Davet, B, 1984
)
0.64
" One of five new quinolones was orally administered, before transurethral resection of the prostate, at the dosage of 200 mg three times daily for 3 consecutive days."( Accumulation of new quinolones in the blood of elderly patients.
Abe, Y; Hasuda, A; Morita, M; Nakagawa, H; Suzuki, K,
)
0.13
"5 mM) by 20% of the control in the in situ ligated loop experiment, in which partial precipitation of aluminum hydroxide was observed in the dosing solution."( Mechanistic study of inhibition of levofloxacin absorption by aluminum hydroxide.
Aoki, H; Fujisawa, C; Hakusui, H; Kurata, T; Ohshima, Y; Okazaki, O; Tanaka, M, 1993
)
0.29
" Enoxacin was selected as a model drug incorporated in various liposome formulations as a therapeutic dosage form using the ethanol injection method and freeze-drying."( Characterization and stability of various liposome-encapsulated enoxacin formulations.
Fang, JY; Hsu, LR; Lin, HH; Tsai, YH, 1997
)
1.45
" At the end of the dosing period, absolute weights of the epididymis were decreased; in contrast, relative weights of testis were increased in the ENX-treated group."( Collaborative work to evaluate toxicity on male reproductive organs by repeated dose studies in rats 19). Effects of two-week repeated dosing of enoxacin on the male reproductive organs.
Furubo, S; Kawamura, Y; Kizawa, K; Sanzen, T, 2000
)
0.51
" Many of the fluoroquinolone agents have once-daily dosing regimens, enhancing patient adherence."( The expanding role of fluoroquinolones.
Schaeffer, AJ, 2002
)
0.31
" In addition, concurrent dosing of BPAA (1 microgram/body) did not reduce the convulsion-inducing dose of PZFX mesilate."( [Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate, a new quinolone antibacterial agent for intravenous use: convulsions in mice after intravenous or intracerebroventricular administration].
Fukuda, H; Kawamura, Y, 2002
)
0.31
" In a second study, two dosage regimens of sitafloxacin were compared with placebo in Oriental subjects."( A randomized controlled trial (volunteer study) of sitafloxacin, enoxacin, levofloxacin and sparfloxacin phototoxicity.
Dawe, RS; Ferguson, J; Ibbotson, SH; Sanderson, JB; Thomson, EM, 2003
)
0.56
" The ECL was satisfactorily applied to the determination of the two FQs in dosage form and urine sample."( Electrochemiluminescence of terbium (III)-two fluoroquinolones-sodium sulfite system in aqueous solution.
Chen, SL; Ding, F; Liu, Y; Zhao, HC, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antibacterial drugA drug used to treat or prevent bacterial infections.
DNA synthesis inhibitorAny substance that inhibits the synthesis of DNA.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
monocarboxylic acidAn oxoacid containing a single carboxy group.
amino acidA carboxylic acid containing one or more amino groups.
1,8-naphthyridine derivativeAny naphthyridine derivative that is a derivative of 1,8-naphthyridine.
N-arylpiperazine
quinolone antibioticAn organonitrogen heterocyclic antibiotic whose structure contains a quinolone or quinolone-related skeleton.
fluoroquinolone antibioticAn organonitrogen heterocyclic antibiotic containing a quinolone (or quinolone-like) moiety and which have a fluorine atom attached to the central ring system.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (27)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency26.60320.006038.004119,952.5996AID1159521
TDP1 proteinHomo sapiens (human)Potency18.64620.000811.382244.6684AID686978; AID686979
EWS/FLI fusion proteinHomo sapiens (human)Potency0.00260.001310.157742.8575AID1259253
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency2.56450.000214.376460.0339AID720691
cytochrome P450 2C9 precursorHomo sapiens (human)Potency15.84890.00636.904339.8107AID883
chromobox protein homolog 1Homo sapiens (human)Potency112.20200.006026.168889.1251AID540317
gemininHomo sapiens (human)Potency0.19950.004611.374133.4983AID624297
lamin isoform A-delta10Homo sapiens (human)Potency1.25890.891312.067628.1838AID1487
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency15.84890.00638.235039.8107AID883
TAR DNA-binding protein 43Homo sapiens (human)Potency39.81071.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
DNA gyrase subunit AEscherichia coli K-12IC50 (µMol)14.00000.02390.56295.2300AID530379
DNA gyrase subunit BEscherichia coli K-12IC50 (µMol)14.00000.00500.43985.2300AID530379
V-type proton ATPase subunit B, brain isoformHomo sapiens (human)IC50 (µMol)10.000010.000010.000010.0000AID430759
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)IC50 (µMol)10.00000.00071.600310.0000AID430759
DNA gyrase subunit BMycobacterium tuberculosis H37RvIC50 (µMol)156.00000.01502.467610.0000AID530368
DNA gyrase subunit AMycobacterium tuberculosis H37RvIC50 (µMol)156.00000.01503.477310.0000AID530368
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)IC50 (µMol)10.00000.00071.630610.0000AID430759
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)IC50 (µMol)10.00000.00061.525710.0000AID430759
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)IC50 (µMol)10.00000.00071.747210.0000AID430759
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)IC50 (µMol)10.00000.00071.741110.0000AID430759
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)IC50 (µMol)10.00000.00071.741110.0000AID430759
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)IC50 (µMol)10.00000.00071.741110.0000AID430759
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RISC-loading complex subunit TARBP2Homo sapiens (human)Kd6.32700.09404.98138.0600AID1692574; AID1884723
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (84)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
DNA topological changeDNA gyrase subunit AEscherichia coli K-12
DNA-templated transcriptionDNA gyrase subunit AEscherichia coli K-12
response to xenobiotic stimulusDNA gyrase subunit AEscherichia coli K-12
DNA-templated DNA replicationDNA gyrase subunit AEscherichia coli K-12
DNA topological changeDNA gyrase subunit AEscherichia coli K-12
response to antibioticDNA gyrase subunit AEscherichia coli K-12
chromosome organizationDNA gyrase subunit AEscherichia coli K-12
negative regulation of DNA-templated DNA replicationDNA gyrase subunit AEscherichia coli K-12
DNA topological changeDNA gyrase subunit BEscherichia coli K-12
DNA-templated transcriptionDNA gyrase subunit BEscherichia coli K-12
response to xenobiotic stimulusDNA gyrase subunit BEscherichia coli K-12
DNA-templated DNA replicationDNA gyrase subunit BEscherichia coli K-12
DNA topological changeDNA gyrase subunit BEscherichia coli K-12
response to antibioticDNA gyrase subunit BEscherichia coli K-12
chromosome organizationDNA gyrase subunit BEscherichia coli K-12
regulation of macroautophagyV-type proton ATPase subunit B, brain isoformHomo sapiens (human)
ATP metabolic processV-type proton ATPase subunit B, brain isoformHomo sapiens (human)
synaptic vesicle lumen acidificationV-type proton ATPase subunit B, brain isoformHomo sapiens (human)
proton transmembrane transportV-type proton ATPase subunit B, brain isoformHomo sapiens (human)
vacuolar acidificationV-type proton ATPase subunit B, brain isoformHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of translationRISC-loading complex subunit TARBP2Homo sapiens (human)
negative regulation of protein kinase activityRISC-loading complex subunit TARBP2Homo sapiens (human)
siRNA processingRISC-loading complex subunit TARBP2Homo sapiens (human)
pre-miRNA processingRISC-loading complex subunit TARBP2Homo sapiens (human)
miRNA processingRISC-loading complex subunit TARBP2Homo sapiens (human)
negative regulation of cytoplasmic pattern recognition receptor signaling pathwayRISC-loading complex subunit TARBP2Homo sapiens (human)
positive regulation of viral genome replicationRISC-loading complex subunit TARBP2Homo sapiens (human)
regulation of viral transcriptionRISC-loading complex subunit TARBP2Homo sapiens (human)
negative regulation of defense response to virus by hostRISC-loading complex subunit TARBP2Homo sapiens (human)
regulation of siRNA processingRISC-loading complex subunit TARBP2Homo sapiens (human)
RISC complex assemblyRISC-loading complex subunit TARBP2Homo sapiens (human)
global gene silencing by mRNA cleavageRISC-loading complex subunit TARBP2Homo sapiens (human)
regulation of miRNA processingRISC-loading complex subunit TARBP2Homo sapiens (human)
regulation of regulatory ncRNA processingRISC-loading complex subunit TARBP2Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (48)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
DNA bindingDNA gyrase subunit AEscherichia coli K-12
DNA topoisomerase activityDNA gyrase subunit AEscherichia coli K-12
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activityDNA gyrase subunit AEscherichia coli K-12
protein bindingDNA gyrase subunit AEscherichia coli K-12
ATP bindingDNA gyrase subunit AEscherichia coli K-12
ATP-dependent activity, acting on DNADNA gyrase subunit AEscherichia coli K-12
DNA negative supercoiling activityDNA gyrase subunit AEscherichia coli K-12
identical protein bindingDNA gyrase subunit AEscherichia coli K-12
DNA bindingDNA gyrase subunit BEscherichia coli K-12
DNA topoisomerase activityDNA gyrase subunit BEscherichia coli K-12
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activityDNA gyrase subunit BEscherichia coli K-12
protein bindingDNA gyrase subunit BEscherichia coli K-12
ATP bindingDNA gyrase subunit BEscherichia coli K-12
ATP-dependent activity, acting on DNADNA gyrase subunit BEscherichia coli K-12
DNA negative supercoiling activityDNA gyrase subunit BEscherichia coli K-12
metal ion bindingDNA gyrase subunit BEscherichia coli K-12
protein bindingV-type proton ATPase subunit B, brain isoformHomo sapiens (human)
ATP bindingV-type proton ATPase subunit B, brain isoformHomo sapiens (human)
proton transmembrane transporter activityV-type proton ATPase subunit B, brain isoformHomo sapiens (human)
proton-transporting ATPase activity, rotational mechanismV-type proton ATPase subunit B, brain isoformHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
pre-miRNA bindingRISC-loading complex subunit TARBP2Homo sapiens (human)
double-stranded RNA bindingRISC-loading complex subunit TARBP2Homo sapiens (human)
protein bindingRISC-loading complex subunit TARBP2Homo sapiens (human)
enzyme bindingRISC-loading complex subunit TARBP2Homo sapiens (human)
siRNA bindingRISC-loading complex subunit TARBP2Homo sapiens (human)
miRNA bindingRISC-loading complex subunit TARBP2Homo sapiens (human)
pre-mRNA bindingRISC-loading complex subunit TARBP2Homo sapiens (human)
identical protein bindingRISC-loading complex subunit TARBP2Homo sapiens (human)
protein homodimerization activityRISC-loading complex subunit TARBP2Homo sapiens (human)
pre-miRNA bindingRISC-loading complex subunit TARBP2Homo sapiens (human)
protein sequestering activityRISC-loading complex subunit TARBP2Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (43)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
chromosomeDNA gyrase subunit AEscherichia coli K-12
cytoplasmDNA gyrase subunit AEscherichia coli K-12
cytosolDNA gyrase subunit AEscherichia coli K-12
membraneDNA gyrase subunit AEscherichia coli K-12
cytoplasmDNA gyrase subunit AEscherichia coli K-12
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) complexDNA gyrase subunit AEscherichia coli K-12
chromosomeDNA gyrase subunit BEscherichia coli K-12
cytoplasmDNA gyrase subunit BEscherichia coli K-12
cytosolDNA gyrase subunit BEscherichia coli K-12
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) complexDNA gyrase subunit BEscherichia coli K-12
ruffleV-type proton ATPase subunit B, brain isoformHomo sapiens (human)
lysosomal membraneV-type proton ATPase subunit B, brain isoformHomo sapiens (human)
cytosolV-type proton ATPase subunit B, brain isoformHomo sapiens (human)
plasma membraneV-type proton ATPase subunit B, brain isoformHomo sapiens (human)
microvillusV-type proton ATPase subunit B, brain isoformHomo sapiens (human)
apical plasma membraneV-type proton ATPase subunit B, brain isoformHomo sapiens (human)
clathrin-coated vesicle membraneV-type proton ATPase subunit B, brain isoformHomo sapiens (human)
melanosomeV-type proton ATPase subunit B, brain isoformHomo sapiens (human)
intracellular membrane-bounded organelleV-type proton ATPase subunit B, brain isoformHomo sapiens (human)
extracellular exosomeV-type proton ATPase subunit B, brain isoformHomo sapiens (human)
extrinsic component of synaptic vesicle membraneV-type proton ATPase subunit B, brain isoformHomo sapiens (human)
vacuolar proton-transporting V-type ATPase, V1 domainV-type proton ATPase subunit B, brain isoformHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmRISC-loading complex subunit TARBP2Homo sapiens (human)
cytoplasmRISC-loading complex subunit TARBP2Homo sapiens (human)
cytosolRISC-loading complex subunit TARBP2Homo sapiens (human)
nuclear bodyRISC-loading complex subunit TARBP2Homo sapiens (human)
perinuclear region of cytoplasmRISC-loading complex subunit TARBP2Homo sapiens (human)
RISC-loading complexRISC-loading complex subunit TARBP2Homo sapiens (human)
RISC complexRISC-loading complex subunit TARBP2Homo sapiens (human)
nucleusRISC-loading complex subunit TARBP2Homo sapiens (human)
cytoplasmRISC-loading complex subunit TARBP2Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (429)

Assay IDTitleYearJournalArticle
AID1292330Permeability of the compound at 100 ug/ml after 18 hrs by PAMPA-BBB assay2016Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10
Synthesis and evaluation of 4-hydroxyl aurone derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID572150Antimicrobial activity against AcrAB-deficient Escherichia coli AG100AX harboring pBAD plasmid after 18 to 24 hrs by two fold dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Functional cloning and characterization of the multidrug efflux pumps NorM from Neisseria gonorrhoeae and YdhE from Escherichia coli.
AID530369Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA A83S mutant2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID1600149Biofilm degradation activity against Staphylococcus aureus ATCC 6538 assessed as biofilm formation at 4 times antibacterial MIC incubated for 24 hrs compound added post-biofilm formation by total biomass crystal violet staining-based method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID430779Effect of mouse MC3T3-E1 cell growth at 50 uM after 3 days2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Identification of enoxacin as an inhibitor of osteoclast formation and bone resorption by structure-based virtual screening.
AID436987Inhibition of human NCI-H460 cell proliferation by sulphorodhamine B assay2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.
AID206570Median effective dose against Staphylococcus aureus 50774 causing systemic infections1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Pyridonecarboxylic acids as antibacterial agents. 2. Synthesis and structure-activity relationships of 1,6,7-trisubstituted 1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids, including enoxacin, a new antibacterial agent.
AID563500Antimicrobial activity against Serratia marcescens ATCC 13880 by broth dilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Mutational upregulation of a resistance-nodulation-cell division-type multidrug efflux pump, SdeAB, upon exposure to a biocide, cetylpyridinium chloride, and antibiotic resistance in Serratia marcescens.
AID430775Antiresorptive activity in mouse MC3T3-E1 cells assessed as effect on osteoblast mineralization at 100 uM after 3 days by Von Kossa assay2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Identification of enoxacin as an inhibitor of osteoclast formation and bone resorption by structure-based virtual screening.
AID430766Antiresorptive activity in 1,25-dihydroxyvitamin D3-stimulated Swiss Webster mouse osteoclast assessed as blockade of ruffled membrane formation on bone slices at 10 uM after 3 days2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Identification of enoxacin as an inhibitor of osteoclast formation and bone resorption by structure-based virtual screening.
AID278245Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-4 gyrA+ with ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278264Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS18 with GyrA S38F mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID349880Permeability across porcine brain lipid coated polyvinylidene fluoride membrane by PAMPA2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease.
AID113422Antibacterial activity (oral efficacy) against systemic infections due to Staphylococcus aureus 50774 microbial strains in mice was determined1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Pyridonecarboxylic acids as antibacterial agents. 9. Synthesis and antibacterial activity of 1-substituted 6-fluoro-1,4-dihydro-4-oxo-7-(4-pyridyl)-1,8-naphthyridine-3- carboxylic acids.
AID1585850Effective permeability of the compound in PBS/EtOH at 100 ug/ml after 18 hrs by PAMPA2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID267739Antibacterial activity against Klebsiella pneumoniae ATCC 10031 by agar-dilution method2006Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13
Synthesis and antibacterial activity of new fluoroquinolones containing a substituted N-(phenethyl)piperazine moiety.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID278237Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-2 gyrA+ with ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID207175Antibacterial activity against Staphylococcus aureus (H228)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID1390040Effective permeability of the compound at 100 ug/ml after 18 hrs by PAMPA-BBB assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
AID1600112Bactericidal activity against methicillin resistant Staphylococcus aureus 6347 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID620399Permeability of the compound by PAMPA2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Hybrids of oxoisoaporphine-tacrine congeners: novel acetylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation inhibitors.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID103832In vitro antibacterial activity against Morganella morganii (A 15153)1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
Fluoronaphthyridines and quinolones as antibacterial agents. 1. Synthesis and structure-activity relationships of new 1-substituted derivatives.
AID568483Antimicrobial activity against methicillin-resistant Staphylococcus aureus N 315 by twofold broth dilution method2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Synthesis and evaluation of a class of new coumarin triazole derivatives as potential antimicrobial agents.
AID1444094Permeability of the compound in PBS/EtOH at 100 ug/ml after 18 hrs by PAMPA-BBB assay2017European journal of medicinal chemistry, Apr-21, Volume: 130Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
AID1703887Permeability of the compound incubated for 165 mins by PAMPA-BBB assay2020European journal of medicinal chemistry, Oct-15, Volume: 204Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID207938In vitro for antibacterial activity against Staphylococcus aureus 209P JC-11984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Pyridonecarboxylic acids as antibacterial agents. 4. Synthesis and antibacterial activity of 7-(3-amino-1-pyrrolidinyl)-1-ethyl-6-fluoro-1,4 -dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid and its analogues.
AID696005Permeability of the compound after 4 hrs by PAMPA assay2012European journal of medicinal chemistry, Dec, Volume: 58Microwave-assisted synthesis of hydroxyphenyl nitrones with protective action against oxidative stress.
AID278243Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-3 tolC::Kan with GyrA S83F, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID210196Compound was tested for inhibition of the gram-negative organism Streptococcus pneumoniae SV-11986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID150898Compound was tested in vitro for antibacterial activity against the microbial strain Pseudomonas aeruginosa 12.1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Pyridonecarboxylic acids as antibacterial agents. 9. Synthesis and antibacterial activity of 1-substituted 6-fluoro-1,4-dihydro-4-oxo-7-(4-pyridyl)-1,8-naphthyridine-3- carboxylic acids.
AID1334753Permeability of the compound at 100 ug/ml after 18 hrs by PAMPA assay2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
AID163963In vitro antibacterial activity against Pseudomonas aeruginosa IFO 3445,Pa(I),(gram-negative)1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Synthesis and antibacterial activity of new tetracyclic quinolone antibacterials.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID278251Antimicrobial activity against Salmonella enterica serovar Typhimurium CS1 tolC::Kan with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID1600107Antibacterial activity against Pseudomonas aeruginosa ATCC 9027 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID96229Compound was tested for inhibition of the gram-negative organism Klebsiella pneumoniae MGH-21986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID163738Compound was tested for inhibition of the gram-negative organism Providencia rettgeri H17711986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID1600147Biofilm degradation activity against Staphylococcus aureus ATCC 6538 assessed as biofilm formation at antibacterial MIC incubated for 24 hrs compound added post-biofilm formation by total biomass crystal violet staining-based method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID113424Antibacterial activity against Pseudomonas aeruginosa 12 microbial strains in mice was determined expressed as ED50 (mg/kg)1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Pyridonecarboxylic acids as antibacterial agents. 9. Synthesis and antibacterial activity of 1-substituted 6-fluoro-1,4-dihydro-4-oxo-7-(4-pyridyl)-1,8-naphthyridine-3- carboxylic acids.
AID278271Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS38 tolC::Kan with GyrA D87G mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID1600114Bactericidal activity against methicillin resistant Staphylococcus epidermidis ATCC 13199 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID1292332Permeability of the compound at 25 ug/ml after 18 hrs by PAMPA-BBB assay2016Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10
Synthesis and evaluation of 4-hydroxyl aurone derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID1496040Effective permeability of the compound in PBS/EtOH at 50 ug/mL after 18 hrs by PAMPA-BBB assay2018Bioorganic & medicinal chemistry letters, 06-15, Volume: 28, Issue:11
Discovery of novel anti-tuberculosis agents with pyrrolo[1,2-a]quinoxaline-based scaffold.
AID1600102Bactericidal activity against Enterococcus hirae ATCC 1052 cultured in BHI medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID467612Fraction unbound in human plasma2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1557284Antibacterial activity against Staphylococcus aureus by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID436992Inhibition of human EJ cell proliferation by MTT assay2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID164290in vitro antibacterial activity against Pseudomonas aeruginosa Tsuchijima1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Pyridonecarboxylic acids as antibacterial agents. 4. Synthesis and antibacterial activity of 7-(3-amino-1-pyrrolidinyl)-1-ethyl-6-fluoro-1,4 -dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid and its analogues.
AID1817221Antiproliferative activity against human QSG7701 cells incubated for 24 hrs by alamar blue assay2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Identification of a Novel TAR RNA-Binding Protein 2 Modulator with Potential Therapeutic Activity against Hepatocellular Carcinoma.
AID467613Volume of distribution at steady state in human2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID278258Antimicrobial activity against Salmonella enterica serovar Typhimurium CS9 acrAB::Kan with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID469403Permeability across PAMPA membrane 2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease.
AID1557292AUC in human at 0.6 g, po2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID208894Compound was tested for inhibition of the gram-negative organism Streptococcus aureus UC-76.1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID1817211Antiproliferative activity against human SK-HEP1 cells assessed as increase in miR-22-5p level at 20 uM by qRT-PCR analysis2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Identification of a Novel TAR RNA-Binding Protein 2 Modulator with Potential Therapeutic Activity against Hepatocellular Carcinoma.
AID278261Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS14 gyrA+ with GyrA D87G mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1817244Antitumor activity in human MHCC97 cells xenografted in SCID mouse assessed as reduction in infiltration of inflammatory cells in left middle lobe of liver at 20 mg/kg, ip measured after 30 days by H and E staining based immunohistochemical analysis2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Identification of a Novel TAR RNA-Binding Protein 2 Modulator with Potential Therapeutic Activity against Hepatocellular Carcinoma.
AID1600095Antibacterial activity against Staphylococcus aureus ATCC 6538 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID1600116Bactericidal activity against Streptococcus pneumoniae cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID227850In vitro antibacterial activity against staphylococcus aureus FDA 209P JC-1,Sa(F)(gram-positive)1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Synthesis and antibacterial activity of new tetracyclic quinolone antibacterials.
AID1653161Cytotoxicity against human A431 cells assessed as reduction in cell viability by MTT assay2019European journal of medicinal chemistry, Mar-01, Volume: 165Quinolone hybrids and their anti-cancer activities: An overview.
AID1495957Effective permeability of the compound in PBS/ethanol buffer after 12 hrs by PAMPA2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Design, synthesis and evaluation of vilazodone-tacrine hybrids as multitarget-directed ligands against depression with cognitive impairment.
AID530373Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA M74I and A83S mutant2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID1437175Permeability of the compound by PAMPA2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
AID1703921Permeability of the compound by PAMPA-BBB assay2020European journal of medicinal chemistry, Oct-15, Volume: 204Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.
AID1600098Bactericidal activity against methicillin resistant Staphylococcus aureus N315 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID64394In vitro antibacterial activity against Enterobacter cloacae (A 9656)1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
Fluoronaphthyridines and quinolones as antibacterial agents. 1. Synthesis and structure-activity relationships of new 1-substituted derivatives.
AID278260Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS14 with GyrA D87G mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID575056Antibacterial activity against Vibrio cholerae O1 mTn-321 harboring Ser to Ile mutation at 83 position in gyrA and parC genes by 2-fold agar dilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Reduced expression of the vca0421 gene of Vibrio cholerae O1 results in innate resistance to ciprofloxacin.
AID278255Antimicrobial activity against Salmonella enterica serovar Typhimurium CS3 tolC::Kan with GyrA S83F, D87N, parC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278240Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-3 with GyrA S83F, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID427197Membrane permeability dissolved in PBS/EtOH (70:30) mixture by PAMPA-BBB assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
AID17991Bioavailability2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Search compounds with antimicrobial activity by applying molecular topology to selected quinolones.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID563503Antimicrobial activity against cetylpyridinium chloride-sensitive Serratia marcescens 79 by broth dilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Mutational upregulation of a resistance-nodulation-cell division-type multidrug efflux pump, SdeAB, upon exposure to a biocide, cetylpyridinium chloride, and antibiotic resistance in Serratia marcescens.
AID430772Antiresorptive activity in mouse MC3T3-E1 cells assessed as effect on osteoblast formation at 1 uM after 3 days2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Identification of enoxacin as an inhibitor of osteoclast formation and bone resorption by structure-based virtual screening.
AID227855In vitro antibacterial activity against staphylococcus epidermidis IAM 1296, (gram-positive)1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Synthesis and antibacterial activity of new tetracyclic quinolone antibacterials.
AID436994Inhibition of human KB cell proliferation by MTT assay2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.
AID1465314Effective permeability of the compound by PAMPA2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Design, synthesis and biological evaluation of 2-acetyl-5-O-(amino-alkyl)phenol derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID563501Antimicrobial activity against cetylpyridinium chloride-resistant Serratia marcescens 01 by broth dilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Mutational upregulation of a resistance-nodulation-cell division-type multidrug efflux pump, SdeAB, upon exposure to a biocide, cetylpyridinium chloride, and antibiotic resistance in Serratia marcescens.
AID568488Antimicrobial activity against Salmonella typhi ATCC 9484 by twofold broth dilution method2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Synthesis and evaluation of a class of new coumarin triazole derivatives as potential antimicrobial agents.
AID530376Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA/GyrB N464S mutant gene2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID436995Inhibition of human SK-MEL cell proliferation by MTT assay2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.
AID575057Antibacterial activity against Escherichia coli JM109 harboring plasmid ptac852010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Reduced expression of the vca0421 gene of Vibrio cholerae O1 results in innate resistance to ciprofloxacin.
AID568486Antimicrobial activity against Escherichia coli ATCC 25922 by twofold broth dilution method2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Synthesis and evaluation of a class of new coumarin triazole derivatives as potential antimicrobial agents.
AID445445Permeability at pH 6.5 by PAMPA method2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID568487Antimicrobial activity against Proteus vulgaris ATCC 6896 by twofold broth dilution method2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Synthesis and evaluation of a class of new coumarin triazole derivatives as potential antimicrobial agents.
AID572147Antimicrobial activity against AcrAB-deficient Escherichia coli AG100AX harboring pBADomeganorM plasmid containing Neisseria gonorrhoeae multidrug efflux pump NorM after 18 to 24 hrs by two fold dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Functional cloning and characterization of the multidrug efflux pumps NorM from Neisseria gonorrhoeae and YdhE from Escherichia coli.
AID278263Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS14 tolC::Kan with GyrA D87G mutant2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID164287Compound was evaluated in vivo for oral antibacterial activity against Pseudomonas aeruginosa 12 at a dose of 4E31984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Pyridonecarboxylic acids as antibacterial agents. 4. Synthesis and antibacterial activity of 7-(3-amino-1-pyrrolidinyl)-1-ethyl-6-fluoro-1,4 -dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid and its analogues.
AID1600148Biofilm degradation activity against Staphylococcus aureus ATCC 6538 assessed as biofilm formation at 2 times antibacterial MIC incubated for 24 hrs compound added post-biofilm formation by total biomass crystal violet staining-based method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID575054Antibacterial activity against Vibrio cholerae O1 569B harboring gyrA and parC genes by 2-fold agar dilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Reduced expression of the vca0421 gene of Vibrio cholerae O1 results in innate resistance to ciprofloxacin.
AID1568822Effective permeability of the compound at 25 ug/ml incubated for 18 hrs by PAMPA-BBB assay2019European journal of medicinal chemistry, Sep-15, Volume: 178Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID200251Compound was tested in vitro for antibacterial activity against the microbial strain Staphylococcus aureus 209P JC-1.1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Pyridonecarboxylic acids as antibacterial agents. 9. Synthesis and antibacterial activity of 1-substituted 6-fluoro-1,4-dihydro-4-oxo-7-(4-pyridyl)-1,8-naphthyridine-3- carboxylic acids.
AID133812Compound was evaluated for protective dose against the Escherichia coli vogel lethal infection following sc administration in mouse1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1557291Cmax in human at 0.6 g, po2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID278235Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-1 tolC::Kan with GyrA S83F mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID1557285Antibacterial activity against Streptococcus pneumoniae by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID278252Antimicrobial activity against Salmonella enterica serovar Typhimurium CS3 with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1192730Permeability of the compound by PAMPA2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer's disease.
AID639368Permeability of the compound by PAMPA assay2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
N-acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease.
AID1653090Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay2019European journal of medicinal chemistry, Mar-01, Volume: 165Quinolone hybrids and their anti-cancer activities: An overview.
AID1557279Antibacterial activity against Escherichia coli by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID70570Compound was tested for inhibition of the gram-negative organism Escherichia coli H5601986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID1557294Protein binding in human at 0.6 g, po2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID1557293Half life in human at 0.6 g, po2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID572151Antimicrobial activity against AcrAB-deficient Escherichia coli AG100AX harboring pBADomegaydhE plasmid containing Escherichia coli multidrug efflux pump YdhE after 18 to 24 hrs by two fold dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Functional cloning and characterization of the multidrug efflux pumps NorM from Neisseria gonorrhoeae and YdhE from Escherichia coli.
AID133813Compound was evaluated for protective dose against the Streptococcus aureus UC-76 lethal infection following po administration in mouse1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID1600130Biofilm degradation activity against Pseudomonas aeruginosa ATCC 9027 assessed as biofilm formation at antibacterial MIC incubated for 24 hrs compound added post-biofilm formation by total biomass crystal violet staining-based method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID637605Permeability of the compound by PAMPA2012European journal of medicinal chemistry, Feb, Volume: 48A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: Structure-based design, synthesis, and biological evaluation.
AID1570001Permeability of compound at 100 ug/ml measured after dilution with PBS/EtOH (70:30) at pH 7.4 after 18 hrs by PAMPA-BBB assay2019European journal of medicinal chemistry, Oct-15, Volume: 180Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease.
AID278248Antimicrobial activity against Salmonella enterica serovar Typhimurium CS1 with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID1347980Permeability of the compound in PBS/EtOH at 100 ug/ml after 12 hrs by PAMPA-BBB assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID530372Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA M74I mutant2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID568484Antimicrobial activity against Bacillus subtilis ATCC 6633 by twofold broth dilution method2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Synthesis and evaluation of a class of new coumarin triazole derivatives as potential antimicrobial agents.
AID198018Activity against Staphylococcus epidermidis (IAM 1296)1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids.
AID430759Inhibition of maltose binding protein-fused human V-ATPase subunit B2 binding to F-actin2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Identification of enoxacin as an inhibitor of osteoclast formation and bone resorption by structure-based virtual screening.
AID1557286Antibacterial activity against Streptococcus pyogenes by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1692578Upregulation of Let-7a mRNA expression in Sprague-Dawley rat frontal cortex at 10 mg/kg, ip administered for 8 days by real-time PCR relative to control2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Modulating microRNA Processing: Enoxacin, the Progenitor of a New Class of Drugs.
AID430778Inhibition of Saccharomyces cerevisiae V-ATPase subunit B expressed in Escherichia coli binding to rabbit muscle actin filament at 100 uM by pelleting assay2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Identification of enoxacin as an inhibitor of osteoclast formation and bone resorption by structure-based virtual screening.
AID1692577Growth inhibition of human DU145 cells incubated for 72 hrs by MTT assay2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Modulating microRNA Processing: Enoxacin, the Progenitor of a New Class of Drugs.
AID530378Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA M74I and A83S mutant/GyrB R447K mutant gene2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID278256Antimicrobial activity against Salmonella enterica serovar Typhimurium CS9 with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID164385Antibacterial activity against Pseudomonas aeruginosa (UI-18)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID164220Median effective dose against Pseudomonas aeruginosa 12 causing systemic infections1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Pyridonecarboxylic acids as antibacterial agents. 2. Synthesis and structure-activity relationships of 1,6,7-trisubstituted 1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids, including enoxacin, a new antibacterial agent.
AID95885Antibacterial activity against Klebsiella pneumonia (MGH-2)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID1390042Effective permeability of the compound at 25 ug/ml after 18 hrs by PAMPA-BBB assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1653162Cytotoxicity against human EJ cells assessed as reduction in cell viability by MTT assay2019European journal of medicinal chemistry, Mar-01, Volume: 165Quinolone hybrids and their anti-cancer activities: An overview.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID197995Activity against Staphylococcus aureus (IID 803)1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids.
AID427196Membrane permeability by PAMPA-BBB assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
AID94133In vitro antibacterial activity against Klebsiella pneumoniae (A 9664)1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
Fluoronaphthyridines and quinolones as antibacterial agents. 1. Synthesis and structure-activity relationships of new 1-substituted derivatives.
AID1480942Permeability of the compound at pH 7.4 at 1 mg/ml after 4 hrs by PAMPA-BBB assay2017European journal of medicinal chemistry, Apr-21, Volume: 130Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia.
AID278234Antimicrobial activity against Salmonella enterica serovar Typhimurium GyrA S21-1 acrAB::Kan with GyrA S83F mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278241Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-3 gyrA+ with ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278232Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-1 GyrA S83F mutant2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID113435Antibacterial activity against Escherichia coli P-5101 microbial strains in mice was determined expressed as ED50 (mg/kg)1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Pyridonecarboxylic acids as antibacterial agents. 9. Synthesis and antibacterial activity of 1-substituted 6-fluoro-1,4-dihydro-4-oxo-7-(4-pyridyl)-1,8-naphthyridine-3- carboxylic acids.
AID568489Antimicrobial activity against Shigella dysenteriae ATCC 49550 by twofold broth dilution method2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Synthesis and evaluation of a class of new coumarin triazole derivatives as potential antimicrobial agents.
AID648667Permeability of the compound in porcine brain lipid assessed as ratio of compound in acceptor plate to amount of compound in donor plate at 5 mg/ml after 10 hrs by PAMPA assay2012Bioorganic & medicinal chemistry letters, Mar-15, Volume: 22, Issue:6
Novel oxoisoaporphine-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.
AID1600110Bactericidal activity against Proteus vulgaris NCTC 4635 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID1510741Antibacterial activity against Escherichia coli infected in mouse2019European journal of medicinal chemistry, Oct-01, Volume: 179Nitroimidazole-containing compounds and their antibacterial and antitubercular activities.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID530377Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA A83S mutant/GyrB R447K mutant gene2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID278239Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-2 tolC::Kan with GyrA S83F, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID1600097Antibacterial activity against methicillin resistant Staphylococcus aureus N315 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID568485Antimicrobial activity against Micrococcus luteus ATCC 4698 by twofold broth dilution method2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Synthesis and evaluation of a class of new coumarin triazole derivatives as potential antimicrobial agents.
AID430780Effect on osteoblast formation from mouse MC3T3-E1 cells assessed as alkaline phosphatase activity at 50 uM after 3 days2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Identification of enoxacin as an inhibitor of osteoclast formation and bone resorption by structure-based virtual screening.
AID430770Antiresorptive activity in 1,25-dihydroxyvitamin D3-stimulated Swiss Webster mouse bone marrow cells assessed as reduction in bone pit formation at 10 uM after 5 days2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Identification of enoxacin as an inhibitor of osteoclast formation and bone resorption by structure-based virtual screening.
AID70860Compound was tested for inhibition of the gram-negative organism Escherichia cloacae HA 26461986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID1692581Upregulation of miR-132 mRNA expression in Sprague-Dawley rat frontal cortex at 10 mg/kg, ip administered for 8 days by real-time PCR relative to control2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Modulating microRNA Processing: Enoxacin, the Progenitor of a New Class of Drugs.
AID1600145Biofilm degradation activity against Pseudomonas aeruginosa ATCC 9027 assessed as biofilm formation at 2 times antibacterial MIC incubated for 24 hrs compound added post-biofilm formation by total biomass crystal violet staining-based method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID1600117Antibacterial activity against Serratia marcescens ATCC 12795 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID278266Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS18 acrAB::Kan with GyrA S38F mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID115928Antibacterial activity against Staphylococcus aureus 50774 microbial strains in mice was determined expressed as MIC1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Pyridonecarboxylic acids as antibacterial agents. 9. Synthesis and antibacterial activity of 1-substituted 6-fluoro-1,4-dihydro-4-oxo-7-(4-pyridyl)-1,8-naphthyridine-3- carboxylic acids.
AID78688Inhibitory concentration in supercoiling inhibition Escherichia coli DNA gyrase assay1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID220994In vitro antibacterial activity against klebsiella pneumoniae B54,Kp,(gram-negative)1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Synthesis and antibacterial activity of new tetracyclic quinolone antibacterials.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID278236Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-2 with GyrA S83F, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID1568812Permeability of the compound in pH 7.4 PBS/EtOH at 100 ug/ml by PAMPA-BBB assay2019European journal of medicinal chemistry, Sep-15, Volume: 178Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID1557184Permeability of the compound at 25 ug/ml by PAMPA-BBB assay2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID68809Compound was evaluated in vivo for oral antibacterial activity against Escherichia coli P-5101 at a dose of 9E61984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Pyridonecarboxylic acids as antibacterial agents. 4. Synthesis and antibacterial activity of 7-(3-amino-1-pyrrolidinyl)-1-ethyl-6-fluoro-1,4 -dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid and its analogues.
AID1817284Antitumor activity against human MHCC97 cells xenografted in SCID mouse assessed as decrease in tumor size at 20 mg/kg, ip administered once every 3 days and measured after 10 days2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Identification of a Novel TAR RNA-Binding Protein 2 Modulator with Potential Therapeutic Activity against Hepatocellular Carcinoma.
AID530368Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA/GyrB2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID1884723Binding affinity to human recombinant TRBP by SPR assay2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Discovery of a Novel Small-Molecule Inhibitor Disrupting TRBP-Dicer Interaction against Hepatocellular Carcinoma via the Modulation of microRNA Biogenesis.
AID206541Compound was evaluated in vivo for oral antibacterial activity against Staphylococcus aureus 50774 at a dose of 5E81984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Pyridonecarboxylic acids as antibacterial agents. 4. Synthesis and antibacterial activity of 7-(3-amino-1-pyrrolidinyl)-1-ethyl-6-fluoro-1,4 -dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid and its analogues.
AID208893Compound was tested for inhibition of the gram-negative organism Streptococcus aureus H228.1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID64076In vitro antibacterial activity against Escherichia coli (A 15119)1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
Fluoronaphthyridines and quinolones as antibacterial agents. 1. Synthesis and structure-activity relationships of new 1-substituted derivatives.
AID436993Inhibition of human SW480 cell proliferation by MTT assay2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.
AID1692574Enhancement of His6-tagged TRBP (unknown origin) expressed in Escherichia coli BL21(DE3) binding to 32P-labeled Let7 precursor RNA assessed as TRBP Kd at 30 uM incubated for 60 mins by liquid scintillation counting method (Rvb = 221 nM)2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Modulating microRNA Processing: Enoxacin, the Progenitor of a New Class of Drugs.
AID1817213Antiproliferative activity against human SK-HEP1 cells assessed as decrease in miR-30a-5p level at 20 uM by qRT-PCR analysis2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Identification of a Novel TAR RNA-Binding Protein 2 Modulator with Potential Therapeutic Activity against Hepatocellular Carcinoma.
AID278250Antimicrobial activity against Salmonella enterica serovar Typhimurium CS1 acrAB::Kan with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID1625122Permeability of the compound in pH 7.4 PBS/EtOH at 100 ug/ml after 18 hrs by PAMPA-BBB assay2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
AID1600146Biofilm degradation activity against Pseudomonas aeruginosa ATCC 9027 assessed as biofilm formation at 4 times antibacterial MIC incubated for 24 hrs compound added post-biofilm formation by total biomass crystal violet staining-based method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID1817212Antiproliferative activity against human SK-HEP1 cells assessed as decrease in miR135a-5p level at 20 uM by qRT-PCR analysis2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Identification of a Novel TAR RNA-Binding Protein 2 Modulator with Potential Therapeutic Activity against Hepatocellular Carcinoma.
AID116912Compound was tested for acute toxicity test with a single oral administration in mice and the median lethal dose as calculated.1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Pyridonecarboxylic acids as antibacterial agents. 2. Synthesis and structure-activity relationships of 1,6,7-trisubstituted 1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids, including enoxacin, a new antibacterial agent.
AID1692579Upregulation of miR-124 mRNA expression in Sprague-Dawley rat frontal cortex at 10 mg/kg, ip administered for 8 days by real-time PCR relative to control2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Modulating microRNA Processing: Enoxacin, the Progenitor of a New Class of Drugs.
AID1557283Antibacterial activity against Haemophilus influenzae with horse blood by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID198023Activity against Streptococcus faecalis (IID 682)1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids.
AID530371Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA A83S, S84A, I85V, F96W and P101M mutant2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID1347981Permeability of the compound at pH 7.4 at 25 ug/ml after 18 hrs by PAMPA-BBB assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1817208Antiproliferative activity against human SK-HEP1 cells assessed as increase in miR-106b-5p level at 20 uM by qRT-PCR analysis2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Identification of a Novel TAR RNA-Binding Protein 2 Modulator with Potential Therapeutic Activity against Hepatocellular Carcinoma.
AID65202In vitro antibacterial activity against Escherichia coli KC-14, Ec(K), (gram-negative)1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Synthesis and antibacterial activity of new tetracyclic quinolone antibacterials.
AID278254Antimicrobial activity against Salmonella enterica serovar Typhimurium CS3 acrAB::Kan with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID1817210Antiproliferative activity against human SK-HEP1 cells assessed as increase in miR-26a-5p level at 20 uM by qRT-PCR analysis2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Identification of a Novel TAR RNA-Binding Protein 2 Modulator with Potential Therapeutic Activity against Hepatocellular Carcinoma.
AID1713986Effective permeability of the compound in PBS/ethanol buffer (9:1) at 25 ug/ml after 10 hrs by UV plate reader based PAMPA-BBB assay2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Multitarget-directed oxoisoaporphine derivatives: Anti-acetylcholinesterase, anti-β-amyloid aggregation and enhanced autophagy activity against Alzheimer's disease.
AID1377752Effective permeability of the compound at 25 ug/ml by PAMPA assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents.
AID635079Permeability of the compound after 2.5 hrs by PAMPA-BBB assay2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model.
AID1600113Antibacterial activity against methicillin resistant Staphylococcus epidermidis ATCC 13199 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID530375Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA/GyrB R447K mutant gene2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID278269Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS38 gyrA+ with GyrA D87G mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278270Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS38 acrAB::Kan with GyrA D87G mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID68965Median effective dose against Escherichia coli P-5101 causing systemic infections1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Pyridonecarboxylic acids as antibacterial agents. 2. Synthesis and structure-activity relationships of 1,6,7-trisubstituted 1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids, including enoxacin, a new antibacterial agent.
AID278262Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS14 acrAB::Kan with GyrA D87G mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID1653163Cytotoxicity against human SW480 cells assessed as reduction in cell viability by MTT assay2019European journal of medicinal chemistry, Mar-01, Volume: 165Quinolone hybrids and their anti-cancer activities: An overview.
AID1817239Antitumor activity in human MHCC97 cells xenografted in SCID mouse assessed as suppression of tumor growth at 20 mg/kg, ip administered once every 3 day for 30 days by bioluminescence analysis2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Identification of a Novel TAR RNA-Binding Protein 2 Modulator with Potential Therapeutic Activity against Hepatocellular Carcinoma.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1600108Bactericidal activity against Pseudomonas aeruginosa ATCC 9027 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID430764Antiresorptive activity in 1,25-dihydroxyvitamin D3-stimulated Swiss Webster mouse osteoclast assessed as blockade of actin ring formation on bone slices at 10 uM after 3 days2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Identification of enoxacin as an inhibitor of osteoclast formation and bone resorption by structure-based virtual screening.
AID94137Activity against Klebsiella pneumoniae (PCI-602)1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids.
AID278253Antimicrobial activity against Salmonella enterica serovar Typhimurium CS3 gyrA+ with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID151194Activity against Pseudomonas cepacia (IID-1341)1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids.
AID563502Antimicrobial activity against cetylpyridinium chloride-sensitive Serratia marcescens 71 by broth dilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Mutational upregulation of a resistance-nodulation-cell division-type multidrug efflux pump, SdeAB, upon exposure to a biocide, cetylpyridinium chloride, and antibiotic resistance in Serratia marcescens.
AID70571Compound was tested for inhibition of the gram-negative organism Escherichia coli vogel1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID278230Antimicrobial activity against Salmonella enterica serovar Typhimurium S21 acrAB::Kan2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID197880In vitro antibacterial activity against Staphylococcus aureus Smith (A9537)1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
Fluoronaphthyridines and quinolones as antibacterial agents. 1. Synthesis and structure-activity relationships of new 1-substituted derivatives.
AID1600104Bactericidal activity against Bacillus subtilis ATCC 6633 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID206858Antibacterial activity against Staphylococcus aureus 209PJC-11984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Pyridonecarboxylic acids as antibacterial agents. 2. Synthesis and structure-activity relationships of 1,6,7-trisubstituted 1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids, including enoxacin, a new antibacterial agent.
AID1557288Antibacterial activity against Clostridium perfringens by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID1129167Permeability of the compound by PAMPA2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis.
AID133807Compound was evaluated for protective dose against Streptococcus pneumoniae SV-1 lethal infection following sc administration1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID278228Antimicrobial activity against Salmonella enterica serovar Typhimurium S212007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID430776Reduction in mouse MC3T3-E1 cell growth at 100 uM after 3 days2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Identification of enoxacin as an inhibitor of osteoclast formation and bone resorption by structure-based virtual screening.
AID64253Activity against Escherichia coli (KC-14)1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids.
AID278238Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-2 acrAB::Kan with GyrA S83F, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID164236Antibacterial activity against Pseudomonas aeruginosa Tsuchijima1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Pyridonecarboxylic acids as antibacterial agents. 2. Synthesis and structure-activity relationships of 1,6,7-trisubstituted 1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids, including enoxacin, a new antibacterial agent.
AID135327BBB penetration classification2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID278229Antimicrobial activity against Salmonella enterica serovar Typhimurium S21 gyrA+2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID1817207Antiproliferative activity against human HeLa cells assessed as increase in miR-21 biogenesis level measured after 24 hrs by luciferase assay2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Identification of a Novel TAR RNA-Binding Protein 2 Modulator with Potential Therapeutic Activity against Hepatocellular Carcinoma.
AID63896Activity against Enterobacter aerogenes (ATCC 13048)1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids.
AID223835In vitro antibacterial activity against Pseudomonas aeruginosa E-2,Pa(E),(gram-negative)1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Synthesis and antibacterial activity of new tetracyclic quinolone antibacterials.
AID1480943Permeability of the compound at pH 7.4 at 5 mg/ml after 18 hrs by PAMPA-BBB assay2017European journal of medicinal chemistry, Apr-21, Volume: 130Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia.
AID9403Activity against Acinetobacter calcoaceticus (AC54)1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids.
AID210022Antibacterial activity against Streptococcus pneumoniae (SV-1)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID1436079Permeability of compound at 25 ug/ml after 18 hrs by PAMPA2017European journal of medicinal chemistry, Jan-27, Volume: 126Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer's disease.
AID1125568Antimalarial activity against blood stage form of Plasmodium falciparum assessed as incorporation of [3H]hypoxanthine after 72 hrs by liquid scintillation counting2014European journal of medicinal chemistry, Apr-22, Volume: 77Emergence of pyrido quinoxalines as new family of antimalarial agents.
AID267737Antibacterial activity against Staphylococcus epidermidis ATCC 12228 by agar-dilution method2006Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13
Synthesis and antibacterial activity of new fluoroquinolones containing a substituted N-(phenethyl)piperazine moiety.
AID1600106Bactericidal activity against Escherichia coli ATCC 8739 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID1557287Antibacterial activity against Enterococcus by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID267738Antibacterial activity against Escherichia coli ATCC 8739 by agar-dilution method2006Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13
Synthesis and antibacterial activity of new fluoroquinolones containing a substituted N-(phenethyl)piperazine moiety.
AID278259Antimicrobial activity against Salmonella enterica serovar Typhimurium CS9 tolC::Kan with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID1230204Permeability of the compound by PAMPA-BBB assay2015Journal of natural products, Jun-26, Volume: 78, Issue:6
In Vitro Inhibitory Effects of 8-O-Demethylmaritidine and Undulatine on Acetylcholinesterase and Their Predicted Penetration across the Blood-Brain Barrier.
AID1600118Bactericidal activity against Serratia marcescens ATCC 12795 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID1336731Permeability of compound at 100 ug/ml after 18 hrs by PAMPA2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID115927Antibacterial activity against Escherichia coli P-5101 microbial strains in mice was determined expressed as MIC1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Pyridonecarboxylic acids as antibacterial agents. 9. Synthesis and antibacterial activity of 1-substituted 6-fluoro-1,4-dihydro-4-oxo-7-(4-pyridyl)-1,8-naphthyridine-3- carboxylic acids.
AID436989Inhibition of human MCF7 cell proliferation by MTT assay2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID278268Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS38 with GyrA D87G mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID427198Membrane permeability dissolved in PBS/EtOH (80:20) mixture by PAMPA-BBB assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
AID1817209Antiproliferative activity against human SK-HEP1 cells assessed as increase in miR-21-5p level at 20 uM by qRT-PCR analysis2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Identification of a Novel TAR RNA-Binding Protein 2 Modulator with Potential Therapeutic Activity against Hepatocellular Carcinoma.
AID1692583Cytotoxicity against human neural progenitor cell by CellTiter-Glo Luminescent Cell Viability Assay2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Modulating microRNA Processing: Enoxacin, the Progenitor of a New Class of Drugs.
AID1600129Antibiofilm activity against Staphylococcus aureus ATCC 6538 assessed as biofilm formation at 0.5 times antibacterial MIC incubated for 24 hrs compound added prior to bacterial biofilm formation by total biomass crystal violet staining-based method relati2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID1404015Permeability of the compound after 2.5 hrs by PAMPA2018European journal of medicinal chemistry, Feb-10, Volume: 145Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors.
AID1437174Permeability of the compound in PBS/EtOH at 100 ug/ml after 18 hrs by PAMPA2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
AID1374215Effective permeability of the compound in PBS/EtOH at 100 ug/ml after 18 hrs by PAMPA-BBB assay2018Bioorganic & medicinal chemistry, 03-01, Volume: 26, Issue:5
Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
AID436988Inhibition of human HeLa cell proliferation2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.
AID278257Antimicrobial activity against Salmonella enterica serovar Typhimurium CS9 gyrA+ with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID1453097Effective permeability of the compound at 100 ug/ml incubated for 18 hrs by PAMPA-BBB assay2017Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12
Design, synthesis and biological evaluation of 3,4-dihydro-2(1H)-quinoline-O-alkylamine derivatives as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
AID1625123Permeability of the compound in pH 7.4 PBS at 200 uL after 18 hrs by PAMPA-BBB assay2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
AID209087Compound was tested for inhibition of the gram-negative organism Streptococcus faecalis MGH-21986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1600126Antibiofilm activity against Pseudomonas aeruginosa ATCC 9027 assessed as biofilm formation at antibacterial MIC incubated for 24 hrs compound added prior to bacterial biofilm formation by total biomass crystal violet staining-based method relative to con2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID69782Antibacterial activity against Escherichia coli (H560)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID1600109Antibacterial activity against Proteus vulgaris NCTC 4635 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID1517838Permeability of the compound in pH 7.4 PBS/EtOH at 25 ug/ml after 18 hrs by PAMPA-BBB assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
AID1900247Permeability of the compound at pH 7.4 PBS/EtOH buffer (70:30) by PAMPA-BBB assay2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy.
AID1557178Permeability of the compound at 100 ug/ml measured after compound dilution in PBS/EtOH buffer (70:30) by PAMPA-BBB assay2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID430763Antiresorptive activity in 1,25-dihydroxyvitamin D3-stimulated Swiss Webster mouse osteoclast assessed as blockade of ruffled membrane formation on bone slices at 1 uM after 3 days2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Identification of enoxacin as an inhibitor of osteoclast formation and bone resorption by structure-based virtual screening.
AID38471Activity against Bacillus subtilis (ATCC 6633)1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids.
AID1600127Antibiofilm activity against Staphylococcus aureus ATCC 6538 assessed as biofilm formation at antibacterial MIC incubated for 24 hrs compound added prior to bacterial biofilm formation by total biomass crystal violet staining-based method relative to cont2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID1334754Permeability of the compound at 25 ug/ml after 18 hrs by PAMPA assay2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID278265Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS18 gyrA+ with GyrA S38F mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID1692573Enhancement of RNA interference pathway in HEK293 cells expressing 293-EGFP and shRNA assessed as increase in siRNA-mediated gene knockdown incubated for 24 hrs by inverted fluorescence microscopy2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Modulating microRNA Processing: Enoxacin, the Progenitor of a New Class of Drugs.
AID1600099Antibacterial activity against Staphylococcus epidermidis ATCC 14990 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID278233Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-1 gyrA+2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID1517867Permeability of compound by PAMPA-BBB assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
AID1495958Effective permeability of the compound in PBS/ethanol buffer2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Design, synthesis and evaluation of vilazodone-tacrine hybrids as multitarget-directed ligands against depression with cognitive impairment.
AID430761Antiresorptive activity in 1,25-dihydroxyvitamin D3-stimulated Swiss Webster mouse bone marrow cells after 5 days2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Identification of enoxacin as an inhibitor of osteoclast formation and bone resorption by structure-based virtual screening.
AID1817214Antiproliferative activity against human SK-HEP1 cells incubated for 24 hrs by alamar blue assay2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Identification of a Novel TAR RNA-Binding Protein 2 Modulator with Potential Therapeutic Activity against Hepatocellular Carcinoma.
AID1765292Permeability of compound by PAMPA-BBB assay2021European journal of medicinal chemistry, Oct-15, Volume: 222Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
AID1465293Effective permeability of the compound at 100 ug/ml by PAMPA-BBB assay2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer's disease.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID64252Activity against Escherichia coli (K-12 C600)1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids.
AID133817Compound was evaluated for protective dose against the Streptococcus pneumoniae SV-1 lethal infection following po administration1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID430773Antiresorptive activity in mouse MC3T3-E1 cells assessed as effect on osteoblast formation at 10 uM after 3 days2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Identification of enoxacin as an inhibitor of osteoclast formation and bone resorption by structure-based virtual screening.
AID430760Antiresorptive activity against 1,25-dihydroxyvitamin D3-stimulated osteoclast formation in Swiss Webster mouse bone marrow cells assessed as reduction of tartrate-resistant acid phosphatase activity after 7 days2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Identification of enoxacin as an inhibitor of osteoclast formation and bone resorption by structure-based virtual screening.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1692582Antiviral activity against ZIKV infected in human neural progenitor cells incubated with cells for 24 hrs prior to viral infection followed by replacement of fresh medium containing compound and measured at 48 hrs post infection by RT-PCR method2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Modulating microRNA Processing: Enoxacin, the Progenitor of a New Class of Drugs.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1600100Bactericidal activity against Staphylococcus epidermidis ATCC 14990 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID267740Antibacterial activity against Pseudomonas aeruginosa ATCC 9027 by agar-dilution method2006Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13
Synthesis and antibacterial activity of new fluoroquinolones containing a substituted N-(phenethyl)piperazine moiety.
AID1600111Antibacterial activity against methicillin resistant Staphylococcus aureus 6347 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID568482Antimicrobial activity against Staphylococcus aureus ATCC 25923 by twofold broth dilution method2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Synthesis and evaluation of a class of new coumarin triazole derivatives as potential antimicrobial agents.
AID530379Inhibition of Escherichia coli DNA gyrase GyrA/GyrB2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID65383In vitro antibacterial activity against Escherichia coli NIHJ JC-2,(gram-negative)1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Synthesis and antibacterial activity of new tetracyclic quinolone antibacterials.
AID1600101Antibacterial activity against Enterococcus hirae ATCC 1052 cultured in BHI medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID278242Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-3 acrAB::Kan with GyrA S83F, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID467611Dissociation constant, pKa of the compound2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID278244Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-4 with GyrA S83F, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID1653160Cytotoxicity against human SK-MEL-3 cells assessed as reduction in cell viability by MTT assay2019European journal of medicinal chemistry, Mar-01, Volume: 165Quinolone hybrids and their anti-cancer activities: An overview.
AID151055In vitro antibacterial activity against Pseudomonas aeruginosa (A 9843)1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
Fluoronaphthyridines and quinolones as antibacterial agents. 1. Synthesis and structure-activity relationships of new 1-substituted derivatives.
AID1192731Permeability of the compound in PBS/EtOH buffer at 100 ug/ml by PAMPA2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer's disease.
AID1692580Upregulation of miR-125a-5p mRNA expression in Sprague-Dawley rat frontal cortex at 10 mg/kg, ip administered for 8 days by real-time PCR relative to control2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Modulating microRNA Processing: Enoxacin, the Progenitor of a New Class of Drugs.
AID575058Antibacterial activity against Escherichia coli JM109 harboring plasmid ptac85-vca04212010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Reduced expression of the vca0421 gene of Vibrio cholerae O1 results in innate resistance to ciprofloxacin.
AID659472Effective permeability across porcine polar brain lipid after 4 hrs by PAMPA2012Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4
5-imino-1,2,4-thiadiazoles: first small molecules as substrate competitive inhibitors of glycogen synthase kinase 3.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1374214Effective permeability of the compound in pH 7.4 buffer after 18 hrs by PAMPA-BBB assay2018Bioorganic & medicinal chemistry, 03-01, Volume: 26, Issue:5
Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
AID430762Antiresorptive activity in 1,25-dihydroxyvitamin D3-stimulated Swiss Webster mouse osteoclast assessed as blockade of actin ring formation on bone slices at 1 uM after 3 days2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Identification of enoxacin as an inhibitor of osteoclast formation and bone resorption by structure-based virtual screening.
AID78709Inhibition of DNA gyrase of Escherichia coli H560 cells1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID1377751Effective permeability of the compound after 2.5 hrs at 25 degC by PAMPA assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents.
AID1496041Effective permeability of the compound by PAMPA-BBB assay2018Bioorganic & medicinal chemistry letters, 06-15, Volume: 28, Issue:11
Discovery of novel anti-tuberculosis agents with pyrrolo[1,2-a]quinoxaline-based scaffold.
AID278246Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-4 acrAB::Kan with GyrA S83F, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID1600105Antibacterial activity against Escherichia coli ATCC 8739 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID530374Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA S69V, A71G, E72D, T73V, M74I, N76K, A83S, S84A, I85V, F96W and P101M mutant2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID430768Antiresorptive activity in 1,25-dihydroxyvitamin D3-stimulated Swiss Webster mouse bone marrow cells assessed as reduction in resorptive area at 25 uM after 5 days2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Identification of enoxacin as an inhibitor of osteoclast formation and bone resorption by structure-based virtual screening.
AID1600128Antibiofilm activity against Pseudomonas aeruginosa ATCC 9027 assessed as biofilm formation at 0.5 times antibacterial MIC incubated for 24 hrs compound added prior to bacterial biofilm formation by total biomass crystal violet staining-based method relat2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID151058Activity against Pseudomonas aeruginosa (E-2)1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids.
AID267735Antibacterial activity against Staphylococcus aureus ATCC 6538p by agar-dilution method2006Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13
Synthesis and antibacterial activity of new fluoroquinolones containing a substituted N-(phenethyl)piperazine moiety.
AID1817241Antimetastatic activity against human MHCC97 cells xenografted in SCID mouse assessed as decrease in liver metastasis at 20 mg/kg, ip administered once every 3 days and measured after 10 days2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Identification of a Novel TAR RNA-Binding Protein 2 Modulator with Potential Therapeutic Activity against Hepatocellular Carcinoma.
AID1557280Antibacterial activity against Pseudomonas aeruginosa by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID1692575Anticancer activity against human HCT116 cells incubated for 5 days by MTT assay2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Modulating microRNA Processing: Enoxacin, the Progenitor of a New Class of Drugs.
AID164709Compound was tested for inhibition of the gram-negative organism Pseudomonas aeruginosa UI-181986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID1585851Effective permeability of the compound by PAMPA2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID209302Compound was tested for inhibition of the gram-negative organism Streptococcus pyogenes C203.1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID69746Antibacterial activity against Escherichia coli NIHJ JC-21984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Pyridonecarboxylic acids as antibacterial agents. 2. Synthesis and structure-activity relationships of 1,6,7-trisubstituted 1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids, including enoxacin, a new antibacterial agent.
AID278247Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-4 tolC::Kan with GyrA S83F, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID430774Reduction in osteoblast formation from mouse MC3T3-E1 cells assessed as alkaline phosphatase activity at 100 uM after 3 days2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Identification of enoxacin as an inhibitor of osteoclast formation and bone resorption by structure-based virtual screening.
AID1600094Lipophilicity, log k of the compound at 100 ug/ml by micellar electrokinetic chromatography2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID436991Inhibition of human A431 cell proliferation by MTT assay2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.
AID70410In vitro antibacterial activity against Escherichia coli NIHJ JC-21984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Pyridonecarboxylic acids as antibacterial agents. 4. Synthesis and antibacterial activity of 7-(3-amino-1-pyrrolidinyl)-1-ethyl-6-fluoro-1,4 -dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid and its analogues.
AID445446Oral bioavailability in human2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID267736Antibacterial activity against Bacillus subtilis ATCC 6633 by agar-dilution method2006Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13
Synthesis and antibacterial activity of new fluoroquinolones containing a substituted N-(phenethyl)piperazine moiety.
AID278267Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS18 tolC::Kan with GyrA S38F mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID1557281Antibacterial activity against Klebsiella by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID1600115Antibacterial activity against Streptococcus pneumoniae cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID1600096Bactericidal activity against Staphylococcus aureus ATCC 6538 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID69784Antibacterial activity against Escherichia coli (vogel)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID197994Activity against Staphylococcus aureus (FDA207PJC-1)1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids.
AID1444095Effective permeability of the compound at pH 7.4 at 25 ug/ml after 18 hrs by PAMPA-BBB assay2017European journal of medicinal chemistry, Apr-21, Volume: 130Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID65381In vitro antibacterial activity against Enterococcus faecalis IID 682,Ec (N),(gram-positive)1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Synthesis and antibacterial activity of new tetracyclic quinolone antibacterials.
AID278249Antimicrobial activity against Salmonella enterica serovar Typhimurium CS1 gyrA+ with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID115921Antibacterial activity against Pseudomonas aeruginosa 12 microbial strains in mice was determined expressed as MIC1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Pyridonecarboxylic acids as antibacterial agents. 9. Synthesis and antibacterial activity of 1-substituted 6-fluoro-1,4-dihydro-4-oxo-7-(4-pyridyl)-1,8-naphthyridine-3- carboxylic acids.
AID430769Antiresorptive activity in 1,25-dihydroxyvitamin D3-stimulated Swiss Webster mouse bone marrow cells at 100 uM after 5 days2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Identification of enoxacin as an inhibitor of osteoclast formation and bone resorption by structure-based virtual screening.
AID430777Cytotoxicity against mouse MC3T3-E1 cells assessed as change in morphology at 100 uM after 3 days2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Identification of enoxacin as an inhibitor of osteoclast formation and bone resorption by structure-based virtual screening.
AID1436078Permeability of compound at 100 ug/ml after 18 hrs by PAMPA2017European journal of medicinal chemistry, Jan-27, Volume: 126Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer's disease.
AID78707MIC at which cleaved DNA (linear) is observed at an intensity relative to oxolinic acid at 10 ug/mL by using Gyrase Induced DNA-Cleavage assay1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1713987Effective permeability of the compound at 25 ug/ml after 18 hrs by UV plate reader based PAMPA-BBB assay2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Multitarget-directed oxoisoaporphine derivatives: Anti-acetylcholinesterase, anti-β-amyloid aggregation and enhanced autophagy activity against Alzheimer's disease.
AID1600103Antibacterial activity against Bacillus subtilis ATCC 6633 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID133810Compound was evaluated for protective dose against the Escherichia coli vogel lethal infection following peroral administration in mouse1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID133815Compound was evaluated for protective dose against the Streptococcus aureus UC-76 lethal infection following sc administration in mouse1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID1557282Antibacterial activity against Bacteroides fragilis by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID278231Antimicrobial activity against Salmonella enterica serovar Typhimurium S21 tolC::Kan2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID1692576Growth inhibition of human LNCaP cells incubated for 72 hrs by MTT assay2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Modulating microRNA Processing: Enoxacin, the Progenitor of a New Class of Drugs.
AID430765Antiresorptive activity in 1,25-dihydroxyvitamin D3-stimulated Swiss Webster mouse osteoclast assessed as blockade of actin ring formation on bone slices at 100 uM after 3 days2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Identification of enoxacin as an inhibitor of osteoclast formation and bone resorption by structure-based virtual screening.
AID530370Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA A83S, S84A and I85V mutant2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID575055Antibacterial activity against Vibrio cholerae O1 CIP0.25-1 harboring Ser to Ile mutation at 83 position in gyrA and parC genes by 2-fold agar dilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Reduced expression of the vca0421 gene of Vibrio cholerae O1 results in innate resistance to ciprofloxacin.
AID430767Antiresorptive activity in 1,25-dihydroxyvitamin D3-stimulated Swiss Webster mouse osteoclast assessed as blockade of ruffled membrane formation on bone slices at 100 uM after 3 days2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Identification of enoxacin as an inhibitor of osteoclast formation and bone resorption by structure-based virtual screening.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID67545Activity against Enterobacter aerogenes2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Search compounds with antimicrobial activity by applying molecular topology to selected quinolones.
AID430771Antiresorptive activity in 1,25-dihydroxyvitamin D3-stimulated Swiss Webster mouse bone marrow cells assessed as reduction in bone pit formation at 25 uM after 5 days2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Identification of enoxacin as an inhibitor of osteoclast formation and bone resorption by structure-based virtual screening.
AID227851In vitro antibacterial activity against staphylococcus aureus IID 803,(gram-positive)1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Synthesis and antibacterial activity of new tetracyclic quinolone antibacterials.
AID1230203Permeability of the compound using PDVF membrane after 2 hrs 45 mins by PAMPA-BBB assay2015Journal of natural products, Jun-26, Volume: 78, Issue:6
In Vitro Inhibitory Effects of 8-O-Demethylmaritidine and Undulatine on Acetylcholinesterase and Their Predicted Penetration across the Blood-Brain Barrier.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID64061Compound was tested in vitro for antibacterial activity against the microbial strain Escherichia coli NIHJ JC-2.1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Pyridonecarboxylic acids as antibacterial agents. 9. Synthesis and antibacterial activity of 1-substituted 6-fluoro-1,4-dihydro-4-oxo-7-(4-pyridyl)-1,8-naphthyridine-3- carboxylic acids.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1346860Human V-type ATPase V1 motor B2 subunit (V-type ATPase)2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Identification of enoxacin as an inhibitor of osteoclast formation and bone resorption by structure-based virtual screening.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (688)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990307 (44.62)18.7374
1990's171 (24.85)18.2507
2000's74 (10.76)29.6817
2010's106 (15.41)24.3611
2020's30 (4.36)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.67

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index40.67 (24.57)
Research Supply Index6.70 (2.92)
Research Growth Index4.48 (4.65)
Search Engine Demand Index65.76 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (40.67)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials74 (10.08%)5.53%
Reviews36 (4.90%)6.00%
Case Studies19 (2.59%)4.05%
Observational0 (0.00%)0.25%
Other605 (82.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]Early Phase 111 participants (Actual)Interventional2014-03-06Terminated(stopped due to Not enough patient enrollment and lack of staffing)
A Randomized, Double-blind, Parallel Group, Single Centre, Phase 1b/2 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Three Orally Administered Doses of Enoxacin (200mg Twice Daily, 400mg Twice Daily and 600mg Twice Dail [NCT04840823]Phase 1/Phase 236 participants (Anticipated)Interventional2021-03-26Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]